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RESTRICTION ENZYME GENERATED NEXT-GENERATION SEQUENCING 
LIBRARIES AND GENETIC RISK MODIFIERS OF BRCA1 MUTATION 
CARRIERS 
Bradley M. Downs, Ph.D. 
University of Nebraska, 2016 
Supervisor: San Ming Wang, M.D. 
Next-generation sequencing (NGS) is a high throughput technique used to sequence 
large amounts of DNA in a short amount of time.  However, a limitation to NGS is that 
the generated data is in a single consensus sequence without distinguishing between 
variants on homologous chromosomes.  Separating or phasing the variants from the 
maternal and paternal chromosomes can provide information about the genetic origin of 
disease and information about how DNA nucleotide alterations interact in cis.  This 
dissertation explores a new technical method of using restriction enzymes during NGS 
library preparation and its ability to increase the amount of phasing information that can 
be derived from NGS data.  This study provides evidence that increasing the fragment 
size of NGS libraries can increase the amount of variant phasing information derived 
from NGS data. 
BRCA1 is a well-known tumor suppressor that, when mutated, predisposes the mutation 
carrier to breast cancer.  BRCA1 mutation carriers have a 44-75% risk of developing 
breast cancer by age 70.  In this study, we used next-generation sequencing data to 
identify germline genetic variants that modify the risk of breast cancer in BRCA1 
mutation carriers.  With the use of both biological and statistical filters, five variants were 
identified that changed breast cancer risk in BRCA1 mutation carriers.  Furthermore, it 
was shown that two of the affected genes alter the growth of BRCA1 mutation breast cell 
	  
lines.  Perhaps, more importantly, the two variants were shown to alter the function of 
the affected genes.  This is the first study to provide functional evidence on how 
common genetic variants can modify the risk of breast cancer in BRCA1 mutation 
carriers.  	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The human genome 
The genome is comprised of all the genetic material encoded as DNA.  For humans 
(Homo sapiens), the genome is comprised of 23 chromosome pairs (44 autosomes and 
2 sex chromosomes) as well as mitochondria DNA.  Every cell within the human body 
with a nucleus has 46 chromosomes, with the exception of germ cells.  Germ cells have 
a haploid genome comprised of 23 chromosomes.  
The human genome can be divided into coding and noncoding sequences.  Coding DNA 
sequences occupy ~2% of the genome and can be transcribed into mRNA which is then 
translated into proteins.  Coding regions are called exons while the noncoding regions 
are called introns, untranslated regions (UTRs), and noncoding exons (NC-Exon).  Once 
a coding region is transcribed into precursor mRNA (pre-mRNA), the primary transcript 
is converted into mature mRNA by the capping of a 7-methylguanosine residue to the 5’ 
terminal end, polyadenylation of the 3’ terminal end, and splicing of the introns. 
Noncoding DNA do not encode protein but may contain genes that are transcribed into 
functional RNA molecules such as ribosomal RNA and microRNAs.  Noncoding DNA 
sequences can also bind transcription factors (ie enhancers, insulators, promoters, etc), 
which can regulate gene expression and/or genomic stability. 
The human Genome project 
Prior to the Human Genome Project, very little was known about the contents of the 
human genome.  The Human Genome Project began in 1990, took thirteen years and 
roughly ~3 billion dollars to complete.  The goal for this project was to, for the first time, 
sequence the entire human genome.  The Project sequenced ~3 billion base pairs and 
~20,500 genes in the genome (http://www.genome.gov/12011238).  The information 
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gained from this project was largely used to construct the human reference genome 
many bioinformatics laboratories still use today.  
Sanger sequencing 
The Human Genome Project relied on the sequencing technique developed by Frederick 
Sanger in 1977 1 .  The Sanger method relies on electrophoretic separation of mixtures 
of randomly terminated extension products.  This type of sequencing uses an automated 
method of fluorescently labeled terminators, capillary electrophoresis separation, and 
automated laser signal detection for improved nucleotide sequence detection.  The 
biggest disadvantage of this method is the slow throughput.  Despite this, Sanger 
sequencing utilizes well-defined chemistry, making it the most accurate method for 
sequencing currently available.   
Next generation sequencing 
In 2004, The National Human Genome Research Institute (NHGRI) initiated a funding 
program with the aim to reduce cost of genome sequencing.  The current high-
throughput DNA sequencing technologies frequently used today is next-generation 
sequencing (NGS) and massive-parallel sequencing.  All NGS platforms monitor the 
sequential addition of nucleotides to immobilize and spatially array DNA templates but 
differ substantially in how these templates are generated and how they are interrogated 
to reveal their sequences 2 .  The increased throughput of NGS reactions comes at the 
cost of read length of 30-400bp compared to Sanger sequencing, which can read 0.5-
1kb.  Because of the short reads, NGS uses resequencing, which compares the density 
and sequence content of shorter reads to a reference genome to make the genome 
map.  The human reference genomes being used today, hg19 and b37, are largely 
constructed from the results of the Human Genome Project.   
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Illumina Sequencing 
All NGS requires the starting material to be converted into a library of sequencing 
reaction templates first (the size of which depends on each sequencing platform’s 
specifications).  Next, platform-specific synthetic DNA adapters are then ligated to the 
end of the library fragments. Depending on the NGS technology, the NGS library is 
either sequenced directly or is amplified first, then sequenced. 
The only NGS platform used in this dissertation was an Illumina HiSeq based NGS.  The 
Illumina HiSeq platform technology uses genomic DNA hybridization and bridge 
amplifies on its specific grafted flowcell.  Bridge amplification on the specific grafted 
flowcell is unique to Illumina NGS technology.  After the genomic library is annealed and 
clonally amplified, a fluorescently labeled reversible terminator is imaged as the dNTPs 
are  
added 3  (Figure 1).  
It is also possible to capture targeted genomic sequences within the NGS library.   
Arguably, the most widely used targeted sequencing method is exome capturing.  These 
targeted regions are first hybridized by DNA bound biotinylated probes.  The biotinylated 
probes can then be captured with the selected target regions 3  (Figure 2).  Sequencing 
only the exons, ~2% of the genome, saves on cost and increases the rate of data 
processing. 
While NGS has fast throughput, it is difficult to align higher levels of diversity to the 
reference genome because of the short reads.  This issue is combated through the use 
of longer read lengths or paired-end/mate-pair sequencing 4 .   Length selection and the 
options of paired-end or singled-end sequencing are options on HiSeq sequencing 
systems.  Once the sequencing run is complete, computational tools are needed analyze 
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the quality of each called nucleotide and to map the sequences to the reference 
genome.   
 
 
Figure 1. Illumina based genomic library construction and Illumina HiSeq based 
NGS.  Once the genomic DNA is sheared to the correct fragment size, the adapters are 
attached to the sequenced library.  The constructed library is then applied to the flow cell 
and clutters are generated by bridge amplification.  After amplification, a fluorescently 
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Figure 2. Exome capture with the Illumina HiSeq based NGS.  Once the genomic 
DNA is processed to an appropriate fragment size, DNA bound biotinylated probes are 
hybridized to the fragmented DNA.  Next, the probes are pulled down and the captured 
DNA is sequenced on the Illumina HiSeq platform 3 . 
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Computational steps used to align Illumina sequenced reads 
Once the sequencing data from the HiSeq run are collected, the low quality sequences, 
which could lead to poor mapping and false positive variant calling need to be removed.  
Quality of sequencing decreases the further the reads are sequenced therefore, Illumina 
recommends that a percentage of the read ends be trimmed.  This percentage is based 
on the length of read during sequencing.  After the low quality sequences are removed, 
software can align the reads to the reference genome. To increase the accuracy of 
insertions, deletions, and repetitive regions of the genome, the reads need to be locally 
realigned.  If the library was amplified via PCR before sequencing, the duplicates must 
be marked to remove errors that might have arisen during the PCR amplification 
process.  The variations between the sequenced library and the reference genome can 
now be called. The next step is to annotate the called variants.  Depending on the type 
of study and the investigator hypothesis, these annotated variants will be analyzed 
further in a study specific manner.   
The cancer genome 
Cancer results when the body is unable to regulate cellular growth.  The study of cancer 
genomes can be divided into two fields of study (i) germline mutations that change the 
risk of developing cancer and (ii) somatic genomic alterations that contribute to 
tumorigenesis, invasion, metastasis, and relapse.   
Somatic mutations are any alterations of the germline DNA sequence in the genome, 
which can be separated into passenger and driver mutations.  Driver mutations are 
mutations of the DNA that gives a selective advantage to a cancer cell.  Passenger 
mutations are mutations that have no fitness effect but may be linked to the genome with 
driver mutations. 
	   8 
Germline mutations are found in every genome within the body and can be passed down 
in a hereditary fashion.  In the general population, familial predispositions for cancer is 
rare, giving evidence that germline mutations that increase the predisposition for cancer 
must also be rare.  The frequency of minor alleles can be defined by the minor allele 
frequency (MAF).  The MAF refers to the frequency at which the allele occurs in a given 
population.  Alleles with a MAF higher than 1 percent are usually considered common 
alleles while a MAF lower than 1 percent is considered rare 5 .  While the rarity of the 
mutation is an important factor when searching for mutations that influence cancer 
development, the mutation’s effect on the cell is also an important factor to consider 
when investigating cancer related germline or somatic mutations.   
Mutations can be categorized by the effect they have on the protein they affect.  
Because of the redundancy of codons (multiple codons can translate the same amino 
acid), silent or synonymous mutations are changes to the DNA nucleotide that do not 
cause a change in amino acid.  Missense or nonsynonymous mutations cause a change 
in the translated amino acid.  Splice mutations affect mRNA processing and can cause 
deletion of exonic translation.  Nonsense or stop gain mutations change the amino acid 
codon into a stop codon leading to a truncated protein product.  The last type of mutation 
is frame shifts or out of frame insertions or deletions.  This type of mutation generally 
causes a premature stop codon, generating a truncated protein.  Nonsense and frame 
shift mutations generally have the largest effect on the translated protein.  Many 
software packages can predict the effects of missense mutations.  However, these 
mutations are generally considered variants of unknown significance until the mutations 
undergo rigorous statistical analysis and/or the effects of the mutation are investigated 
by functional assays.   
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Breast cancer 
Breast cancer is the most frequent cancer diagnosis in women with an estimated 1.38 
million new diagnoses worldwide in 2008 6 .  In the United States, the chance of a 
woman being diagnosed with breast cancer during her lifetime is one in eight 7 .  About 
10% of women diagnosed with breast cancer have a hereditary predisposition for breast  
cancer 8,9 .  BRCA1 and BRCA2 are the most common autodominant predisposition for 
hereditary breast cancer and also the most well studied, comprising ~20% of all familial 
breast cancer cases.   Interestingly, ~50% of the familial breast cancer cases have an 
unknown predisposition mutation and are thus labeled as BRCAx 10  (Figure 3).   
This dissertation covers a wide range of topics including analyzing new methods of NGS 
library construction, investigating potentially new breast cancer predisposition mutations 
and the identification and characterization of genetic germline modifiers that change the 
risk of developing breast cancer in BRCA1 mutation carriers.   
  





Figure 3.  Hereditary predispositions of breast cancer.  All breast cancer cases can 
be separated into sporadic cases and cases with germline predisposition mutations.  
Mutations in the BRCA genes comprise 20% of all familial breast cancers.  The other 
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1.1 Introduction 
1.1.1 Current limitations of NGS ability to phase the human genome 
Homo sapiens genomes are diploid, receiving one chromosome copy from their mother 
and one copy form their father.  Genome phasing is the process of separating the 
maternal and paternal chromosomes from a single genome. Information derived from 
genomic phasing can provide the genetic origin of disease and information about how 
DNA nucleotide alterations interact in cis. Currently, most sequencing techniques 
generate a single consensus sequence without distinguishing between variants on 
homologous chromosomes.  
Since the conception of next generation sequencing, both the throughput and 
sequencing read length has increased substantially.  However, even with the advances 
of NGS technology, the biggest disadvantage of NGS system is the relatively short read 
length of 30-400bp, depending on the NGS platform.  Due to the short read length, NGS 
relies on the method of resequencing to map the reads to the correct position on the 
reference genome.  While this method has been shown to accurately map sequenced 
reads to a reference genome, it is unable to phase the sequenced chromosomes.   
1.1.2 Phase information derived from NGS  
Once the genomic libraries are sequenced on the Illumina HiSeq 2000 platform, there 
are 3 NGS read combinations that can be used to construct contigs and provide variant 
phasing information; variants can be phased i) in the same read, ii) in different reads, or 
iii) by paired reads (Figure 4).  These 3 NGS read combinations can be integrated to 
phase multiple variants on a single contig.  
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Figure 4. Next-generation sequencing read combinations providing variant 
phasing information. The three next generation sequencing reads that can be used to 
construct contigs and provide variant phasing information are i) variants phased in the 
same read, ii) variants phased in different reads, iii) variants phased in pair-end reads.  
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1.1.3 Computational and experimental approaches to phase the genome 
There are two NGS approaches used for phasing the genome: computational and 
experimental.  Experimental approaches attempt to phase the genome prior to 
sequencing and relies on the physical separation of the chromosomes.  The 
computational approach attempts to phase the genome post-sequencing.   This method 
uses statistics to estimate the probability that two variants are linked and thus providing 
phase information.  Computational phasing is mostly used to reconstruct haplotypes 
within a single pedigree.  Neither computational nor experimental approaches are 
commonly used because they are thought to be too experimentally laborious and/or 
computationally underpowered.  In the following project, we propose the use of a new 
experimental approach that is not experimentally laborious and has the potential to 
improve the ability of NGS to phase the genome.   
1.1.4 Using restriction enzymes to construct NGS libraries 
There are two types of experimental approaches that can be used to increase the 
phasing ability of next-generation sequencing.  One can either i) improve NGS platform 
technology so longer reads can be sequenced or ii) redesign the method of genomic 
library construction.  This study will investigate a new method of genomic library 
construction.   
Currently, the process of making a genomic library is as follows: DNA shearing by 
sonication, ligation of adapters, selection of exons (if preferred), selection of size, and 
sequencing of DNA library (Figure 1).  We propose that if DNA were specifically cut with 
restriction enzymes, instead of random shearing, there would be a two-fold effect: i) the 
library construct size would be more variable which will increase the size of overlapping 
sequenced data (contigs) and thus increase the number of phased variants and ii) the 
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number of variant errors due to low quality reads will decrease with the new ability to 
filter low quality reads lacking restriction sites.   
1.1.5 Selection of restriction enzyme  
The Illumina HiSeq 2000 platform has an optimal fragment sequencing length of 150-
200 base pairs.  The accuracy of the Illumina system to sequence reads decreases with 
fragments sizes larger than 200 bases pairs.  Because of this limitation, the restriction 
enzymes chosen for genomic DNA digestion must be selected based on average 
digestion fragment length.  Furthermore, because restriction digest sites are fixed, unlike 
random shotgun sequencing, multiple restriction enzyme libraries will need to be pooled 
to get adequate genomic coverage.  Based on the average genomic digestion fragment 
length, 4 restriction enzymes, MluC1, Alu1, HypCH4V, and Fat1 were selected to 
generate 4 different restriction enzyme fragmented NGS libraries (Table 1).  To 
increases the rate of data processing, all of the restriction enzyme NGS libraries 
underwent exome capture before being sequenced on the Illumina HiSeq 2000. 
1.1.6 Genomic DNA sample selection 
Parents and offspring trios are commonly used in phasing experiments due to the ability 
to track inherited variants in the offspring.  Because we are interested in genome 
phasing, we decided to use the genomic DNA from a daughter of a trio (daughter 
NA19240, mother NA19238 and father NA19239), which were collected during the 1000 
Genomes project.  This daughter, NA19240, was chosen because the parents’ and 
daughter’s variants have already been identified and are freely available from the 
Complete Genomic database.  Furthermore, the daughters genomic DNA is 
commercially available. The daughters exome has also been captured using the same 
exome capture kit and ran on the same NGS platform (Illumina HiSeq 2000) as the 
libraries made with the restriction enzymes. 
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Table 1. Average genomic digested fragment length by restriction enzyme 














fragment length 144 241 216 225 150-200 
|, cutting site of restriction enzyme 
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This raw sequenced data is freely available for download from the Complete Genomic 
database.  To compare the two methods of NGS library construction accurately, we ran 
both the raw data from the restriction enzyme libraries and the raw data from the 
Complete Genomic database in parallel through a single bioinformatics pipeline.   
It was hypothesized that the NGS libraries constructed with fragments generated by 
restriction enzyme would be more variable in size in comparison to libraries generated 
from sonication. This variability of fragment size was predicted to increase the contig 
size and thus increase the number of phased variants.  It was also hypothesized that 
number of variant errors due to low quality reads will decrease in the restriction enzyme 
generated NGS libraries in comparison to libraries generated by sonication because of 
the unique ability to filter low quality reads that lacked restriction sites at the end of 
reads.   
1.2 Methods 
1.2.1 Genomic DNA used to generate restriction enzyme exome libraries 
NA19240 genomic DNA was purchased from Coriel DNA depository. 
NA19240 Illumina exonic sequencing data and variant file was downloaded from 
Complete Genomics database. 
1.2.2 Restriction enzyme generated TruSeq DNA sample preparation 
1.2.2.1 Restriction Digestion 
Each restriction enzyme generated TruSeq DNA sample had the starting concentration 
of 1.5 µg of genomic DNA.  Each restriction enzyme digestion reaction was performed 
with 1 unit of enzyme per 1µg of DNA.  The enzymatic incubation time for each sample 
was  
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1 hour.  For enzymes MluC1 (NEB), Alu1 (NEB) and HypCH4V (NEB), 5µl of 10X Buffer 
4 (NEB), 1.25µl of enzyme (1000u/ml) and 43µl ddH20 was added to 1.25µl of gDNA 
(1µg/µl) and incubated at 37˚C for 1 hour.  For enzyme Fat1 (NEB), 5µl of 10X Buffer 2 
(NEB), 1.25µl of Enzyme (1000u/ml) and 43µl H20 was added to 1.25µl of genomic DNA 
(1µg/µl) and incubated at 55˚C for 1 hour.  Immediately after digestion, all reactions were 
cleaned using the QIAquick Nucleotide Removal Kit (QIAGEN) and eluted with 50µl 
ddH20 with an expected 90% retention (~4.5µg). 
1.2.2.2 Blunting and phosphorylating the gDNA 
To repair the 3’ recessed ends made by the enzymes MluC1 and Fat1 and to 
phosphorylate the 5’ end, 10µl of phosphorylation reaction buffer 10X (NEB), 5µl of T4 
DNA polymerase (3u/µl, NEB), 5µl of T4 polynucleotide kinase (10u/µl, NEB), 4µl of 
dNTPs (10mM), and 40µl of H20 was added to 50µl of fragmented DNA (0.9µg/ml) and 
incubated at 20˚C for 30 minutes.  Immediately after blunting and phosphorylating, all 
reactions were cleaned using the QIAquick Nucleotide Removal Kit (QIAGEN) and 
eluted with 32µ ddH20 with expected 80% retention (~3.6µg). 
1.2.2.3 Adenylate of the 3’ end of the blunt DNA fragments 
12.5µl of A-Tailing Mix (Ilumina) was added to 15µl of repaired DNA (67ng/µl) and 
incubated for 30 minutes at 37˚C.   
1.2.2.4 Ligating the Adaptors 
2.5µl of DNA Ligase Mix (Ilumina) and 2.5µl of DNA Adapter (Ilumina) was added to the 
27.5µl of DNA with A-Tails (above) and incubated for 10 minutes at 30˚C.  DNA adapter 
index 4 (Ilumina) was ligated to the library construct with Alu1.  DNA adapter index 5 
(Ilumina) was ligated to the library constructed with HypCH4V.  DNA adapter index 2 
(Ilumina) was ligated to the library constructed with Mlu1.  DNA adapter index 7 (Ilumina) 
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was ligated to the library constructed with Fat1.  After incubation, 5µl of Stop Ligase Mix 
(Ilumina) was added.  The DNA library was then cleaned up twice with AMPure XP 
Beads and resuspended in 22.5µl of Resuspension Buffer (Ilumina).   
1.2.2.5 Library Enrichment 
5µl of Primer Cocktail (Ilumina) and 25µl of PCR Master Mix (Ilumina) was then added to 
1µg of ligated DNA.  The library was then amplified on a thermal cycler with the following 
conditions: 98˚C for 30 seconds, 10 cycles of (98˚C for 10 seconds, 60˚C for 30 seconds 
and 72˚C for 30 seconds), 72˚C for 5 minutes and hold at 4˚C.  The reaction was then 
purified with AMPure XP Beads and re-suspended in 32.5µl of Resuspension Buffer 
(Ilumina).   
1.2.2.6 Exome Enrichment 
Enrichment of the restriction enzyme library exome was performed following the 
standard Illumina protocol “TruSeq Enrichment Guide”.  The TruSeq Exome Enrichment 
kit targets 62 million bases.  The restriction enzyme generated TruSeq exome enriched 
DNA sample were sequenced at 100 bp pair-end reads in one flow cell in an Illumina 
sequencer HiSeq 2000.  The subsequent sequences were processed by the standard 
Illumina sequence quality-control pipeline. 
Exome sequences were mapped to the human genome reference sequence hg19 by 
BWA using the default parameters in paired mode 12 . The resulting SAM files were 
converted to BAM files and duplicates were removed using Picard 
(http://picard.sourceforge.net). The mapped reads were locally realigned using GATK 
RealignerTargetCreator 13 .  Finally the variants were called with GATK following GATK 
best practice protocol (Figure 5).  To call phased data GATK, ‘ReadBackedPhasing’ was 
used 13 . 
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Figure 5. GATK best practice flow cart (http://gatkforums.broadinstitute.org/). 
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1.3 Results 
1.3.1 Mapping sequenced reads 
The restriction enzymes (MluC1, Alu1, HypCH4V and Fat1) were chosen based on the 
average genomic digest fragment length of the restriction enzyme (Table 1).  These four 
restriction enzyme generated exome NGS libraries were pooled and sequenced together 
and reached 109X coverage and covered 87% of the 62 million TruSeq targeted 
sequences (Table 2).  Next, we analyzed if pooling different combinations of restriction 
enzyme libraries would increase the percentage of the exome covered (Figure 6).  By 
combining four different restriction enzyme libraries, we are able to nearly double the 
amount of exome covered in comparison to an exome covered by a single restriction 
enzyme library (46% to 86%).  While the exome NGS library generated by sonication 
reached 20X coverage, it only covered 76% of the 62 million TruSeq targeted 
sequences.   
Interestingly, ~10% of the reads from the restriction enzyme libraries were unable to be 
mapped to the human reference genome hg19.  This is likely a result of either the library 
reads length being outside of Illumina sequencing technology specifications or reads 
being too short to align specifically to the reference genome. Reads that did not include 
a restriction enzyme sequence at the start of the sequenced read (0.7% of the reads) 
were removed from the data set.   
Next, we compared the average paired end fragment length from the restriction enzyme 
libraries to the fragment length generation by sonication.  While the average read length 
is comparable between the two libraries (174nt for restriction enzymes, 179nt for 
sonication) the restriction enzyme libraries standard deviation was much greater than the 
sonication library (174 ±120nt and 179 ±59nt, respectively).  
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Reads 35,514,484 54,521,560 44,955,256 49,058,158 184,049,458 32,740,442 
%  100 100 100 100 100 100 
       
Unmapped 
reads 4,714,350 6,354,982 4,519,560 4,358,828 19,947,720 188,494  
%  13 12 10 9 11 1 
       
Mapped 
reads 30,800,134 48,166,578 40,435,696 44,699,330 164,101,738 32,551,948 
%  87 88 90 91 89 99 




320,751 4,116,781 2,726,051 1,205,967 8,369,550 - 
%  1 8 7 3 5 - 





266,300 35,148  232,294  622,713 1,156,455 - 
%  .8 .08 .06 1 .7 - 




30,213,083 43,694,649 37,477,351 42,870,650 154,255,733 32,551,948 
%  85 80 83 87 84 100 




30,213,083 43,694,649 37,477,351 42,870,650 154,255,733 32,551,948 
%  100 100 100 100 100 100 




16,696,935 22,455,881 20,099,998 22,960,533 82,213,347 16,815,776 
%  55 51 54 54 53 52 
       
nt mapped to 
exome 1,381,746,304 1,858,148,710 1,665,029,685 1,884,831,045 6,789,755,744 1,221,211,997 
X coverage 
to exome 22 30 27 30 109 20 
% exome 
covered 45.14 50.71 45.14 41.98 86.53 76.05 
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Figure 6.  Pooling restriction enzyme libraries increases the percent of exome 
nucleotides covered.  After pooling the four restriction enzyme libraries, the percentage 

























Number of  combined restriction enzyme libraries  
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1.3.2 GATK called variants 
After the poor quality reads (paired reads that mapped alternatively or reads without 
restriction enzyme ends) were removed from both the restriction enzyme libraries and 
sonication library data, the variant caller GATK was used to call variants from both data 
sets.  To compare specificity and sensitivity of the variant calling between the two 
datasets, the amount of overlapping variants between the two datasets with the 
published variant list from Complete Genomics was analyzed.  The Complete Genomic 
variant list was compiled from multiple sequencing runs of the NA19240 genome and is 
considered a highly accurate variant list.  The restriction enzyme libraries showed higher 
sensitivity to call variants (172,571 variants) in comparison to the sonication library 
(79,330 variants).  However, this high sensitivity to call variants in restriction enzyme 
libraries was accompanied with a low specificity. 49% of the variants from the restriction 
enzyme libraries overlapped with the Complete Genomic variant list compared to 97% of 
the sonication library variants overlapped (Table 3).  This high error rate might be due to 
the inability of the restriction enzyme libraries to mark PCR amplified duplicate reads.  
This is because PCR amplified reads are indistinguishable from multiple reads cut at the 
same restriction enzyme site (Figure 7). 
To increase the specificity of variant calling with the restriction enzyme libraries, only 
variants that were covered by two different restriction enzyme library reads were called.  
With this new constraint, the variants called from the sonication library had greater 
sensitivity and specificity than the restriction enzyme library. 79,330 variants called 
compared to 47,194 variants called, respectively. 
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Table 3.  Comparison of GATK called variants from restriction enzyme reads 




Overlapping with Complete 
Genomics variants (%) 
Variants called from both restriction 
enzyme reads and sonication reads 53,508 (31) 52,999 (99) 
Variants called from restriction 
enzyme reads and not called from 
sonication reads 
119,063 (69) 30,837 (26) 
Total number of variants from 
restriction enzyme reads 172,571 (100) 83,886 (49) 
   
Variants called from both sonication 
reads and restriction enzyme reads 53,508 (67) 52,999 (99) 
Variants called from sonication reads 
and not called from restriction 
enzyme reads 
25,822 (33) 24,885 (94) 
Total number of variants from 
sonication reads 79,330 (100) 77,884 (98) 
 
  




Figure 7.  Mapped reads generated by sonication and restriction enzymes.   
A) Fragmenting the genomic DNA by sonication produces randomized fragments.   
B) Restriction enzyme generated libraries produces non-randomized fragments that are 
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Furthermore, 98% of the sonication library variants overlapped with the Complete 
Genomic variant list compared to 97% overlap with the restriction enzyme libraries  
(Table 4). 
1.3.3 Phasing variants 
To compare the ability of sonication and restriction enzyme libraries to phase variants, 
GATK ‘ReadBackedPhasing’ was used to call phased variants.  To obtain an accurate 
comparison, only variants that were called by both sonication and restriction enzyme 
libraries (53,508 variants) were phased.  The number of phased contigs were similar 
between the two techniques (11,936 contigs in restriction enzyme library and 11,494 
contigs in sonication library) (Table5).  While the occurrence of contigs with two phased 
variants are greater in the sonication library, the restriction enzyme libraries constantly 
had a higher occurrence of contigs with >2 variants phased together than the sonication 
library. 
1.4 Discussion 
In this project, I proposed a new method of genomic library construction.  It was 
hypothesized that if random shearing of the genomic DNA was changed to precise 
cutting of DNA with restriction enzymes, the variant error rate would decrease and the 
amount of phased variants would increase because the library fragment size would be 
more variable. 
The results from this study showed both the benefits and problems with construction of 
the genomic NGS library using restriction enzymes.  The first problem is that there are 
10-fold more unmapped reads than a library constructed by sonication.  These 
unmapped reads are comprised of reads that are too small to be aligned to the reference 
human genome.   
	   28 
Table 4.  Comparison of GATK called variants from ≥2 restriction enzyme library 







Variants called from both ≥2 restriction 
enzyme library reads and sonication 
reads 
30,644 (65) 30,464 (99) 
Variants called from ≥2 restriction 
enzyme library reads and not called from 
sonication reads 
16,550 (35) 15,462 (93) 
Total number of variants from ≥2 
restriction enzyme library reads 47,194 (100) 45,926 (97) 
   
Variants called from both sonication and 
≥2 restriction enzyme library reads 30,644 (39) 30,464 (99) 
Variants called from sonication reads 
and not called from ≥2 restriction 
enzyme library reads 
48,593 (61) 47,432 (98) 
Total number of variants from sonication 
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Table 5.  Phased variants per contig from restriction enzyme and sonication 
libraries 
 
Number of contigs 
Number of phased 
variants per contig Restriction enzyme library Sonication library 
2 5,538 6,503 
3 2,815 2,593 
4 1,433 1,114 
5 788 554 
6 476 272 
7 292 161 
8 181 98 
9 109 62 
10 97 45 
11 55 28 
12 41 19 
13 26 14 
14 18 10 
15 12 6 
16 12 3 
17 7 4 
18 11 3 
19 12 2 
20 4 0 
21 3 2 
22 2 0 
23 1 1 
24 0 0 
25 0 0 
26 0 0 
27 1 0 
28 1 0 
29 0 0 
30 0 0 
31 0 0 
32 1 0 
Total contigs 11,936 11,494 
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Applying strict read size selection to the methodology of restriction enzyme library 
construction may help correct this result. 
While low quality reads lacking in restriction sequence ends could be filtered out with this 
new method, the inability to distinguish between PCR duplicate reads and non-PRC 
duplicate reads with the restriction enzyme libraries lead to a greater variant calling error 
rate in comparison to the NGS library generated by the sonication of genomic DNA.  
Because of this limitation, it was decided that only variants that were found in 
overlapping restriction enzyme libraries should be called.  While this filter decreased the 
variant calling error rate of the restriction enzyme dataset, libraries generated by 
sonication could still call variants with more specificity and sensitivity in comparison to 
the restriction enzyme libraries.   
Finally, we compared the ability of the two differently generated NGS libraries to call 
phased variants.  While the total number of contigs with phased variant were similar 
between the restriction enzyme library and sonication library, the number of contigs with 
>2 variants phased was consistently more in the restriction enzyme library.  This 
observation is most likely due to the increased standard deviation read length in the 

















CHAPTER 2. Identification and characterization of genetic modifiers of breast 
cancer risk in BRCA1 mutation carriers 
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2.1 Introduction 
Breast cancer cases can be separated into two broad categories, sporadic cases and 
cases with germline mutations.  Sporadic breast cancer make up 90% of all breast 
cancer cases 11 .  The remaining 10% have some type of germline mutations that 
predisposes the carrier for the development of breast cancer 14-17 .  There are many 
known germline genes that increase the risk of developing breast cancer 8,10,18-21 .  One 
of the most common breast cancer germline mutations, which affects about 10% of all 
germline mutation carriers, are mutations in the gene BRCA1 10  (Figure 3). 
2.1.2 BRCA1 
BRCA1 (breast cancer 1, early onset) is a well-known tumor suppressor implicated in a 
diverse array of biological processes, including DNA break repair, cell-cycle checkpoint 
activation, transcription regulation and DNA replication 22-31 .  BRCA1 is located on 
chromosome 17 and is comprised of 24 exons spanning 81,188 bp.  BRCA1 mutation 
carriers from familial breast cancer families have a 44-75% risk of developing breast 
cancer by age 70 15 .  This wide range of risk is due to different risk modifying factors.  
These factors include specificity of the BRCA1 germline mutation, environmental 
modifiers, and genetic modifiers 16,17,21,32-38 . 
2.1.3 Genetic modifiers of breast cancer risk 
Genetic modifiers of cancer risk has been hypothesized for over 20 years.  In the mid-
1990s, cancer risk modifying alleles were first described in mice cancer models 39-41 .  
While there have been many large genome wide association studies (GWAS) that 
associated germline variants with a change of risk of breast cancer in BRCA1 germline 
mutation carriers, there have been no follow up functional studies providing evidence 
that these variants are actually the risk modifiers 42-45  (Table 6).  There are a number of 
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reasons why these variants have not been analyzed further.  The main reason is the 
inability to distinguish whether the identified variants are merely linked to the risk 
modification or if the variant itself is the cause of change of breast cancer risk.  Many of 
the BRCA1 risk modifier GWAS studies used a 610k array SNP chip to genotype the 
BRCA1 mutations carriers, of which 95% of the variants were from intronic or intergenic 
regions of the genome (Figure 8).  While intronic and intergenic regions are no longer 
considered “junk DNA”, the functional consequence of variants in these regions is 
difficult to predict. 
2.1.4 Intervention options of BRCA1 mutation carriers 
Currently, there are limited risk assessments and availability in options for the 
intervention of breast cancer in high-risk women, leading some carriers to undergo an 
invasive mastectomy.  Identifying germline modifiers can both provide better 
personalized cancer risk assessments to BRCA1 mutation carriers and can potentially 
lead to new therapies that may lower the risk for these carriers. 
2.1.5 Benefits of NGS analysis 
To identify variants that have a functional possibility of modifying the risk of developing 
breast cancer in BRCA1 carriers, we used NGS to sequence the exome of 54 BRCA1 
mutation carriers.   Using NGS will increase sensitivity for variant detection in 
comparison to an array SNP chip.  This increase in sensitivity will allow the usage of 
biological filters, which will increase the likelihood of finding functional risk modifying 
variants.  The first biological filter used in this study will be variant function prediction 
software.  All variants that are predicted to be non-damaging to the function of the gene 
will be filtered out as their influence on the affected gene are less predictable. 
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Table 6. Summary of published genetic modifiers of breast cancer risk in BRCA1 mutation carriers 
SNPs GENE Molecular consequence Affected Unaffected HR MAF P Ref Function 
rs4808611 NR2F6 intronic 4144 3362 1.27 0.102 1.6-10  42  - 
rs8100241 ANKLE1 exonic (SIFT Damaging) 4151 3368 0.89 0.46 1.6
-10  42  - 
rs2363956 ANKLE1 exonic (SIFT Damaging) 4150 3367 0.84 0.46 2.4
-10  42  - 
rs67397200 
ANKLE1, 
intergenic 5301 3699 1.16 0.17 4.5-10  43  - 
ABHD8 
rs8170 BABAM1 synonymous 5890 4380 1.23 0.11 2.1-9  43  - 
rs3745185 BABAM1 intronic 4152 3369 0.86 0.31 7.1-8  42  - 
rs6138178 SNRPB intronic 3451 0.78 0.428 0.0015  45  - 
rs6602595 CAMK1D intronic 3451 1.25 0.481 0.0019  45  - 
rs1048635 TRIM45 UTR3 3451 1.5 0.06 0.0029  45  - 
rs13387042 
TNP1, 
intergenic 4763 4268 1.18 0.147 0.005  44  - 
DIRC3 
rs6590224 KIRREL3 intronic 3451 1.26 0.247 0.0056  45  - 
HR, Hazard Ratio 
MAF, Minor allele frequency 
Ref, References  
  




Figure 8. Distribution of variants on the 610k array.  A large percentage of SNPs 
analyzed on the 610k array are in intronic and intragenic regions.  Molecular 







*nonsynonymous, stopgain, stoploss and splicing 













610K array SNP distribution 
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To further increase the likelihood of selecting a functionally relevant variant, a PubMed 
literature search will be used to select only variants that occur in genes that have 
predicted roles in cancer.  It is important to note that genes with unknown functions and 
variants that have no effect on the translated amino acid may, in fact, affect BRCA1 
mutation carrier breast cancer risk.  However, because this study will analyze the 
functional consequence of these variants using in vitro assays, strict filters will be used 
to increase the likelihood of accomplishing this goal.  
2.2 Materials and Methods 
2.2.1 Statistical association study 
2.2.1.1 Samples used in the case control study 
The samples used in this study are from Creighton University Breast Cancer Family 
Registry. Participants provided written informed consent for cancer genetic study. 
Institutional Review Board of Creighton University and Institutional Review Board 
University of Nebraska Medical Center approved the study (CU #00-12265, UNMC 
#718-11-EP). 
The cases included 27 BRCA1 mutated carriers that were diagnosed with breast cancer. 
All breast cancer affected cases were matched with a control breast cancer unaffected 
individual that shared the same BRCA1 mutation from the same family.  If multiple 
breast cancer affected carriers were available, the individual diagnosed at the earliest 
age was selected.  If multiple unaffected carriers were available, the oldest individual 
was selected.  In total there were 27 cases and 27 controls from 27 families.   
2.2.1.2 Samples used in the cohort study 
The BRCA1 mutated carrier sample size was increased from 54 BRCA1 mutation 
carriers in the case control study to 161 BRCA1 mutation carriers in the cohort study.  
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These 107 new BRCA1 mutation cases were only selected based on the BRCA1 
mutation status.   
2.2.1.3 Statistical association of genetic modifiers to breast cancer risk  
Odds ratio (OR) and their 95% confidence intervals (CI) were estimated using the 
unconditional maximum likelihood with the R package Epitools software.  The variants 
that passed the biological filters and odds ratio statistics were then re-analyzed in a 
cohort study using the Cox regression model 46 .  The Hazard Ratio (HR), their 95% 
confidence interval (CI) and Wald’s P-value were calculated using the R package 
Survival software. 
2.2.1.4 Illumina Exome libraries preparation  
DNA from blood cells was extracted from the selected BRCA1 mutation carriers by Dr. 
Lynch’s laboratory and was shipped to Dr. San Ming Wang’s lab for analysis.  The 
exome libraries were prepared and captured by using the SureSelectXT2 Target 
Enrichment System (Agilent Technologies, which has a total amount of targeted 
sequence of 75 million bases.  The libraries were sequenced in an Illumina sequencing 
platform HiSeq 2500 with 150bp paired-end reads with the goal of 50X coverage, based 
on nucleotides mapped to the exome.   
2.2.1.5 Mapping, variant calling and damaging prediction 
After samples were sequenced, the last 25% of each read was trimmed with fastqx-
trimmer 47  before being mapped to the human reference genome hg19 by the program 
BWA 48 .  Once mapped, the reads were locally realigned and the duplicates were 
marked with Picard  49 .  The variants were then called with the program 
GATK_HaplotypeCaller following GATK best practice protocol 50  (Figure 5). All of the 
variants were analyzed with the program AnnoVar 51 . The computer software PolyPhen2 
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and Sift was used to determine if the change in amino acid would likely be damaging to 
the function of the protein 52,53 . 
2.2.1.6 PCR products Sanger sequenced 
The 5’ and 3’ oligonucleotide primers were manually designed for each DNA sequenced 
and were ordered from IDT.  To genotype the BRCA1 mutation carriers, the following 
primers were used. 
SYNE1_ rs2295190 
F 5’- TTGCTTATGACCCGATCCTC-3’    
R 5’- GAAGGTGCAGAGGCAAAAAG-3’   
ANKLE1_ rs8100241 
F 5’- GAGACGCTGGACTCCATAGC-3’    
R 5’- CAGCTCCAGAGACCTCAACC-3’   
ANLN_rs3735400 
F 5’- GCTGAAAGAGAATGGGGTTTT-3’    
R 5’- GCAGATGTCGACTCAACTGG-3’   
SIPA1L2_ rs1547742 
F 5’- AAGAACAGCCAGCCACCTTA-3’    
R 5’- CCTCAGTGGTTCTCACCATTC-3’   
MTHFSD_ rs3751800 
F 5’- CAGGGCTCTCTTCAGGTCAC-3’    
R 5’- GCCTGGAGATGATGGAGAAA-3’   
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PCR were carried out in a PTC-200 thermal cycler (MJ Research).  The following 
components are added to the final PCR master mix: 15ng of DNA template, 0.1mM 
dNTP mixture, 1X GoTaq buffer (Promega), 1µM primers (5’ and 3’), and 1u/µl GoTaq 
(Promega).  First, the template DNA was denatured at 95˚C for 7 minutes.  Next, 38 
cycles of 95˚C for 30sec, 57˚C for 30sec, 72˚C 45sec (depending on expected fragment 
size, 1kb=45sec).  The last PCR cycle was a final extension of 72˚C for 7 minutes.  
Before the sequences are Sanger sequenced, the PCR products are cleaned with SAP 
(1u/µg of DNA), 1X SAP buffer, and Exo1 (1u/µg of DNA).  This reaction was incubated 
at 37˚C for 60 minutes and denatured at 95˚C for 20 minutes before the primer is 
premixed with the sample and sent for Sanger sequencing.   
2.2.2 Functional Study 
2.2.2.1 Bacterial strains 
NEB 10-beta electrocompetent E. coli genotype: ∆(ara-leu)7697 araD139 fhuA ∆lacX74 
galK16 galE15 e14- Φ80dlacZ∆M15 recA1 relA1 endA1 nupG rpsl (StrR)rph spoT1 
∆(mrr-hsdRMS-mcrBC) 
XL10-Gold ultracompetent E. coli genotype: TetR ∆(mcrA)183 ∆(mcrCB-hadSMR-mrr) 
173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Htee [F’ proAB laclqZ∆M15 Tn10 (TetR) 
Amy CamR].   
2.2.2.2 Bacterial Cell Growth Conditions 
LB media was made with 10g NaCl, 10g tryptone, 5g yeast extract (per liter of media) 
and pH to 7.0 with 5N NaOH.  If solid media was required, 20g of agar per liter was 
added before sterilization by autoclaving.  Once the sterilized LB media cooled, 
depending on desired antibiotic selection, kanamycin (50µg/ml), ampicillin (100µg/ml), or 
carbenicillin (100µg/ml) was added.   
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E. coli cells inoculated in liquid LB media was grown in a C24 incubator shaker (New 
Brunswick Scientific) at 37˚C, 200 rpm overnight.  E. coli cells inoculated on solid LB 
media was grown at 37˚C overnight.   
2.2.2.3 Bacterial transformation 
2.2.2.3.1 Electorcompetent transformation 
1µl of DNA was added to E. coli beta-10 cells in a chilled 1mm electroporation cuvette 
(Bioexpress) and mixed by flicking gently.  Cells were shocked with the Bio-Rad 
micropulser at 2.0 kv, 200Ω, and 25µF, 975µl pre-warmed (37˚C) SOC outgrowth 
medium was transferred to the cuvette and then transferred to a culture tube.  The cells 
were then shaken vigorously (250 rpm) at 37˚C for 1h, then spread onto four pre-
warmed LB selection plates and incubated overnight at 37˚C.   
2.2.2.3.2 Chemical competent transformation 
45µl of XL10-Gold cells was added to a pre-chilled 14-ml polypropylene tube, 2µl of β-
mercaptoethanol was added.  Cells were incubated on ice and swirled gently every 2 
minutes for 10 minutes, then 2µl of DNA was added to the ultracompetent cells.  After 
the cells were incubated on ice for 30 minutes, the cells were heat-pulsed in a 42˚C 
water bath for 30s.  The heat-pulsed cells were then incubated on ice for two minutes 
before 0.5ml of preheated (42˚C) SOC media was added.  These cells were incubated at 
37˚C for one hour at 250 rpm before the cells are spread onto four pre-warmed LB 
selection plates and incubated overnight at 37˚C.  Plasmid DNA was purified with the 
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2.2.2.4 Mammalian Cell line Growth Conditions  
HCC1937 cell line was grown at 37˚C, 5% CO2 atmosphere in Roswell Park Memorial 
Institute medium (RPMI 1640, ATCC) supplemented with 10% FBS (Gibco), and 1X 
streptomycin/penicillin (Gibco). 
HEK 293T cell line was grown at 37˚C, 5% CO2 atmosphere in Dulbecco’s Modified 
Eagle Medium (DMEM, ATCC) supplemented with 10% FBS, and 1X 
streptomycin/penicillin. 
HeLa cell line was grown at 37˚C, 5% CO2 atmosphere in Dulbecco’s Modified Eagle 
Medium (DMEM, HyClone) supplemented with 10% FBS, and 1X streptomycin/penicillin. 
MCF7 cell line was grown at 37˚C, 5% CO2 atmosphere in Eagle’s Minimum Essential 
Medium (EMEM, ATCC) supplemented with 10ug/ml insulin from bovine pancreas, 10% 
FBS, and 1X streptomycin/penicillin. 
2.2.2.5 shRNA stable cell line production 
E. coli LX10 gold carrying packaging plasmid psPAX2, envelope plasmid pMD2.G, and 
scramble shRNA (on the vector backbone pLKO.1) were purchased from Addgene.  
ANLN shRNA (TRCN0000117257) bacterial glycerol stock were purchased from Sigma-
Aldrich.   
2.2.2.6 Lentiviral particles production 
To start the lentiviral particle packaging, 7×105 HEK-293T cells were plated on a 6 cm 
tissue culture plate at 37˚C, 5% CO2 in DMEM +10% FBS without antibiotics overnight.  
After 12-15 hours, a plasmid cocktail of 1µg pLKO.1, 750ng psPAX2, 250 ng pMD2.G 
was added to 20µl of OPTI-MEM (Invitrogen).  Next 10µl of Lipofectamine 2000 
(Invitorgen) was added to 90 µl of OPTI-MEM (Gibco) and incubated at room 
temperature of 5 minutes.  The lipofectamine 2000 master mix was then added to the 
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plasmid cocktail and incubated for 20-30 minutes at room temperature.  This mixture 
was then added to the cells and incubated at 37˚C, 5% CO2 overnight.  In the morning, 
fresh media with antibiotics was added and the cells were incubated at 37˚C, 5% CO2 for 
24 hours.   After 24 hours, the media was harvested and 5ml of fresh media containing 
antibiotics was added to the cells and incubated at 37˚C, 5% CO2 for 24 hours. Again, 
after 24 hours, the cells were harvested.  The harvested media was then filtered through 
a 0.45µm filter and stored at -20˚C.  SYNE1 shRNA infection particles 
(TRCN0000147281) were purchased from Sigma-Aldrich. 
2.2.2.7 Infecting Target Cells 
Target cells were plated at 50% confluence at 37˚C, 5% CO2 overnight.  The next 
morning, fresh culture media containing 8µg/ml polybrene (Santa Cruz) was added.  
Next, 0.5ml of lentiviral particles was added to the target cells and incubated at 37˚C, 5% 
CO2 for 24 hours.  The media was then changed after 24 hours.  Two days after 
infection, stable cell lines were selected using 1µg/ml of puromycin (Sigma-Aldrich).   
2.2.2.8 DNA Transfection Procedure 
Target cells were plated in a 6-well plate in growth medium without antibiotics at 37˚C, 
5% CO2 for 24 hours.  Once the cells were 90% confluent, 4.0µg of DNA was diluted in 
250µl of Opti-MEM and 10µl of Lipofectamine 2000 diluted in 250µl of Opti-MEM.  After 
5 minutes of incubation at room temperature, the diluted DNA was combined with the 
diluted Lipofectamine 2000 and incubated for 20 minutes at room temperature.  The 
complexes were added to the cells and medium and mixed by gently rocking the plate 
back and fourth.  Cells were grown for 48 hours before imaging or selective medium was 
added.   
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2.2.2.9 Growth curve  
Stable shRNA cells were seeded at 3.0×104 in 6-well plates with complete EMEM media 
without antibiotics.  The seeded cells were allowed to grow for 24 hours before the first 
time point was collected.  The following time points were collected every 24 hours for 
five more days.  Cell viability was determined with 0.04% trypan blue (Gibco).  Cells 
were counted manually with a hemocytometer (Bright-Line).   
2.2.2.10 Microscopy  
Two days after transient transfection, cells were transferred and grown on a glass 
coverslip for 24 hours.  Cells were then fixed with 4% paraformaldehyde in PBS.  DAPI 
Fluoromount-G was used to mount and stain the nucleus.  These cells were then imaged 
on a Nikon Eclipse TI-E microscope with a Nikon Digital sight DS-QiMc camera.  Images 
were overlaid in NIS Elements (Nikon) and fluorescence intensity were measured with 
the software ImageJ. 
2.2.2.11 Western Blot 
To extract whole cell lysate from living cells, a lysing buffer (5% glycerol, 1.5% SDS) was 
added directly to the cells.  Proteins were then denatured at 95˚C for 10 minutes and 
protein concentrations were measured using a BCA protein assay Kit (Pierce) on an 
iMark microplate absorbance reader (Bio Rad).   
Proteins were separated by SDS-PAGE and transferred to nitrocellulose membrane 
(Immobilon-P) for subsequent blotting with antibodies.  Both SYNE1 and ANLN proteins 
were separated by a 9% SDS-PAGE gel.  To blot for ANLN, a monoclonal anti-ANLN 
AMAB90660 antibody produced in mouse was used (Sigma-Aldrich) while SYNE1 was 
probed using a monoclonal anti-SYNE1 SAB1404967 antibody produced in mouse 
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(Sigma-Aldrich).  To blot Hsc70, a monoclonal anti-Hsc70 ab19136 antibody produced in 
mouse was used (abcam).  The secondary antibody used for all western blot assays was 
anti-mouse IgG, HRP-linked antibody 7076s (Cell Signaling Technology).  All blots were 
developed on Blue Lite Autorad Film (GeneMate).   
2.2.2.12 ANLN construct design and verification 
Overexpressing eGFP-anillin vector was a gift from Dr. Andrew Wilde’s lab 54 . The 
variant was induced with overlapping oligonucleotides with the QuickChange 2 XL Site-
Directed Mutagenesis Kit (Agilent Technologies).   
Oligonucleotides used to induce the variant in the ANLN_rs3735400 construct: 
F 5’- gagaaatcttgtacaaaaccatGgccatcaaaaaaacgctg-3’  
R 5’-cagcgtttttttgatggcCatggttttgtacaagatttctc-3’.   
To verify the induced variant, the vector was Sanger sequenced with primer: 
 5’-CTGCACCTGAGGAGACACAG-3’. 
To generate the eGFP vector without anillin, the following primers were used to amplify 
only the vector backbone. 
F 5’- aatggatccgtttacggagaaactgc -3’    
R 5’- ctacaaacctattggaaagccttaa -3’   
After the vector backbone was made, DpnI endonuclease (10 U/µl) was incubated with 
the PCR product at 37˚C for 1 hour to digest the plasmid construct.  To add 5’ phosphate 
to the DNA sequence, T4 polynucleotide kinase (NEB) (10U/µl) with 1x T4 ligase buffer 
was incubated at 37˚C for 1 hour.  To ligase the DNA sequence, T4 DNA ligase (NEB) 
(1U/µl) was incubated with the DNA sequence at room temperature for 2 hours.   
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2.2.2.13 SYNE1 construct design and verification 
EGFP-C2_DN-Nesprin-1 vector was a gift from Dr. Angelika Noegel’s lab 55 .  The 
variant was induced with overlapping oligonucleotides with the QuickChange 2 XL Site-
Directed Mutagenesis Kit (Agilent Technologies).   
Oligonucleotides used to induce variant in the SYNE1_rs2295190 construct: 
F 5’-gtgggtcgagccttcAtgttccggatcctc-3’  
R 5’-gaggatccggaacaTgaaggctcgacccac-3’ 
To verify the induced variant, the vector was Sanger sequenced with primer: 
5’-TGTGAGTCCCACATCCGGAA-3’  
2.3 Results  
2.3.1 Statistical association study 
2.3.1.1 BRCA1 mutated carriers sample selection 
To increase the chance of identifying variants that modify the risk of developing breast 
cancer in BRCA1 mutation carriers, we set strict criteria for sample selection.  All of the 
BRCA1 mutation carriers’ mutations must be listed in breast cancer information core 
(BIC) database as clinically important and/or large deletions of BRCA1 must have been 
identified.  Because the specificity of the BRCA1 mutation has been shown to modify the 
risk of breast cancer, the breast cancer affected and unaffected mutation carriers were 
matched by the specificity of their mutation 32-34 .  Furthermore, because age is a strong 
risk factor for breast cancer development, the affected and unaffected individuals were 
also matched by at least 5 years 16 .  To increase the likelihood of identifying variants 
that increase the risk of developing breast cancer, the youngest breast cancer affected 
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case was selected if multiple cases were available.  Likewise, to increase the chance of 
identifying variants that decreased the risk of developing breast cancer, the oldest breast 
and ovarian cancer unaffected BRCA1 mutation carrier was selected if multiple cases 
were available.  There were 27 BRCA1 mutated carriers that were diagnosed with breast 
cancer and 27 BRCA1 mutated carriers unaffected by breast cancer from 27 families 
that matched all selection criteria (Table 7).   
2.3.1.2 NGS mapping, variant calling and variant annotation 
All 54 genomes were then processed into 54 NGS exome libraries using the 
SureselectXT2 exome+UTR capture kit.  This capture kit was designed to capture 75 
million nucleotides per genome.  The libraries were sequenced on the Illumina HiSeq 
2500 at 150bp pair-end reads with 2.67 libraries seeded per lane.  After the 54 samples 
were sequenced, the average depth of sequenced reads in the exome was 66.5 (66.5X 
coverage) (Table 8).  The 54 samples also had, on average, 97.5 percent of the 75 
million nucleotides captured.  While GATK called, on average, over 1 million variants per 
sample, the 54 samples had on average 2,105 variants predicted damaging by 
PolyPhen2 or SIFT per genome (Table 9).   
2.3.1.3 Case control study to identify candidate genetic modifiers 
2.3.1.3.1 Previously identified breast and/or risk modifying variants   
CIMBA and other laboratories have previously published genetic variants that 
statistically modify the risk of breast and ovarian cancer  17,21,37,56,57 .  Most of these 
studies extracted genomic data through the use of SNP arrays.  These arrays are 
significantly less expensive than NGS.  This method of genotyping allowed these 
laboratories to genotype many thousands of samples per analysis.   
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1 Polish 1008 bp del-exon 17 - F 31 56 57 1.56 
2 Irish 1623del5-ter503 yes F 35 57 62 50 
3 Ashkenazi Jewish 185delAG-ter39 yes F 37 64 56 25 








185delAG-ter39 yes F 36 56 57 12.5 
6 English/Irish 188del11-ter36 yes F 31 58 71 6.25 
7 English/Irish/ Scottish 
254-1G-T-
exon5 yes F 22 68 58 50 
8 Irish 2841Glu-ter (G-T) yes F 27 50 56 50 
9 Dutch/ Indian 
300Cys-Gly (T-






Gins59-ter75 yes F 35 75 78 6.25 
11 Scandinavian 5272-2delA-exon 19 yes F 38 69 64 50 
12 Caucasian 5382insC-ter1829 yes F 33 72 63 3.125 
13 Russian/ Jewish 
5382insC-
ter1829 yes F 32 61 62 3.125 
14 Ashkenazi Jewish 
5382insC-
ter1829 yes F 44 82 49 50 
15 Unknown 5622Arg-terC-T yes F 32 60 61 50 
16 German/ English 
882Glu-ter (G-
T) yes F 35 56 54 50 
17 Irish/French 916delTT-ter285 yes F 24 56 58 3.125 
18 Caucasian del37kb (exons 1-2) - F 36 72 80 12.5 
19 German Exon 11 1240delC yes F 38 56 69 25 





yes F 29 60 56 12.5 
22 Czech/ German 
Exon 16 
C4808G yes F 27 64 73 25 
23 German/ English Glu143ter yes F 28 56 53 50 






ter1460 yes F 39 61 58 50 
26 Dutch/German IVS12-1632del3835 yes F 29 51 74 1.56 
27 German/ Polish IVS6-2delA yes F 34 56 58 50 
Average     34 63 62 25 
 
BIC, breast cancer information core 
BC diag, breast cancer diagnosed  
  
  
	   48 
Table 8. Breast cancer cases and controls sequenced with Illumina HiSeq 2500 




Affected	   Unaffected	   Affected	   Unaffected	   Affected	   Unaffected	   Affected	   Unaffected	  
	  
Reads	  aligned	  to	  
Exome+UTR	   nt	  mapped	  to	  Exome+UTR	   X	  coverage	  
%	  of	  covered	  nt	  in	  
Exome+UTR	  
1	   86,482,134	   56,073,196	   7,650,127,187	   5,081,972,608	   103	   68	   99.8	   99.7	  
2	   69,068,541	   48,956,004	   6,394,426,226	   4,522,927,280	   86	   61	   99.1	   99	  
3	   47,886,957	   77,915,392	   4,441,973,829	   7,135,423,515	   60	   96	   97.6	   99.1	  
4	   21,985,934	   13,626,780	   2,074,862,383	   1,276,001,973	   38	   17	   93.6	   91.8	  
5	   55,116,882	   47,775,867	   5,098,710,336	   4,436,831,644	   68	   59	   99.2	   99	  
6	   55,166,279	   79,944,830	   5,066,027,968	   7,361,958,066	   68	   99	   99.3	   98.6	  
7	   60,172,743	   80,817,890	   5,508,038,601	   7,437,637,846	   74	   100	   99.3	   99.5	  
8	   37,734,040	   59,774,690	   3,543,666,305	   5,464,037,573	   48	   73	   98.6	   99.5	  
9	   18,011,958	   18,187,259	   1,614,674,303	   1,640,546,264	   22	   22	   99	   99	  
10	   72,771,441	   84,314,028	   6,689,109,600	   7,764,194,016	   90	   104	   99.2	   99.5	  
11	   66,480,847	   39,019,760	   6,146,505,581	   3,644,376,137	   82	   49	   98.9	   97.9	  
12	   35,765,547	   54,349,173	   3,366,493,766	   5,039,766,988	   45	   68	   96.3	   98.1	  
13	   56,547,996	   51,214,730	   5,267,931,073	   4,772,844,570	   71	   64	   98.7	   68.7	  
14	   38,511,142	   56,675,359	   3,612,334,201	   5,341,321,374	   48	   72	   96.7	   96.8	  
15	   54,378,902	   84,654,781	   4,886,131,853	   7,637,212,363	   66	   102	   99.7	   99.7	  
16	   41,335,655	   62,937,605	   3,856,415,232	   5,840,077,590	   52	   78	   98.4	   98.8	  
17	   12,612,972	   85,809,640	   1,146,953,942	   7,930,384,563	   15	   106	   95.6	   99	  
18	   43,517,923	   58,476,261	   4,032,437,129	   5,418,436,409	   54	   73	   97.9	   98.6	  
19	   69,286,743	   53,981,810	   6,408,976,368	   4,982,461,829	   86	   67	   99.2	   99.3	  
20	   63,541,452	   46,826,633	   5,962,051,678	   4,376,285,715	   80	   59	   97.8	   97.3	  
21	   57,691,353	   60,787,449	   5,322,148,179	   5,630,617,835	   71	   76	   98.9	   99	  
22	   42,236,230	   70,764,096	   3,866,064,306	   6,456,266,070	   52	   87	   99.3	   99.5	  
23	   27,344,435	   48,757,397	   2,462,470,795	   4,387,785,253	   33	   59	   99.3	   99.7	  
24	   62,454,282	   61,252,680	   5,694,441,590	   5,602,955,013	   76	   75	   99.5	   99.4	  
25	   24,193,171	   68,955,803	   2,262,053,398	   6,365,367,452	   30	   85	   95.6	   99.3	  
26	   19,207,071	   48,099,604	   1,745,532,463	   4,492,557,879	   23	   60	   98.6	   98.5	  
27	   76,433,608	   46,069,340	   7,086,838,681	   4,232,751,636	   95	   57	   99.4	   92.5	  
Average	   48,738,379	   58,000,669	   4,489,162,851	   5,343,444,424	   61	   72	   98	   97	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Table 9. Breast cancer cases and controls variants called with GATK and 
analyzed with PolyPhen2 and SIFT 
Samples in 
families Total Variants Total Exonic Variants 
Total Predicted Damaging 
Variants 
 Affected Unaffected Affected Unaffected Affected Unaffected 
1 978,062 1,113,898 19,372 20,724 2,412 2,159 
2 1,636,156 900,886 19,134 19,093 2,136 2,189 
3 1,085,031 1,743,506 18,259 18,745 2,078 2,025 
4 679,774 474,424 15,422 14,659 1,698 1,597 
5 1,082,048 936,887 19,530 19,179 2,144 2,136 
6 1,223,782 1,204,419 18,931 19,169 2,123 2,150 
7 1,319,263 1,225,337 20,681 19,894 2,524 2,271 
8 814,889 1,377,287 19,211 19,342 2,133 2,167 
9 294,220 316,551 18,890 18,687 2,127 2,052 
10 1,263,491 1,424,578 19,513 19,184 2,220 2,101 
11 1,370,974 901,320 19,285 18,623 2,133 2,064 
12 1,029,280 1,586,600 17,270 18,605 1,974 2,102 
13 1,351,599 1,175,098 18,995 18,636 2,112 2,077 
14 1,134,786 1,500,802 17,515 19,401 2,003 2,320 
15 1,013,404 1,254,739 19,677 19,727 2,133 2,140 
16 780,891 1,611,728 18,690 18,200 2,096 1,949 
17 313,035 1,910,332 16,012 18,130 1,741 1,997 
18 1,025,958 1,198,271 18,683 18,939 2,106 2,103 
19 996,549 1,415,127 19,020 18,930 2,241 2,137 
20 1,202,093 838,836 19,131 19,422 2,148 2,151 
21 1,654,218 1,315,488 17,828 17,893 1,991 2,027 
22 1,362,266 1,320,138 19,065 19,294 2,138 2,186 
23 1,046,242 1,497,137 19,259 18,954 2,180 2,057 
24 505,466 734,575 19,269 20,258 2,140 2,269 
25 1,311,678 1,418,653 19,096 18,745 2,123 2,031 
26 424,269 1,155,242 17,294 19,658 1,875 2,192 
27 467,546 1,036,908 18,490 19,132 2,061 2,157 
Average 1,359,857 962,818 19,609 19,067 2,189 2,085 
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Because we are only analyzing the variants from 54 samples, we must first verify that we 
have the sensitivity to call variants that are true positives.  To do this, we first identified 
variants previously published to change the risk of breast or ovarian cancer.   
We hypothesized that if our sample size was large enough to identify previously 
identified genetic risk modifiers, we would also be able to identify new genetic risk 
modifiers.   
To identify these previously identified variants, the Odds Ratio was calculated on the 
variants predicted damaged by either PolyPhen2 or SIFT.  Each variant that segregated 
differently between the breast cancer affected and unaffected with the statistical 
significance of P≤ 0.15 were analyzed further through a search in PubMed.  The 
PubMed search found two variants previously identified to change the risk of breast or 
ovarian cancer (Figure 9).  The variant rs8100241 in ANKLE1 has been identified by 
CIMBA to decrease the risk of breast cancer in BRCA1 mutation carriers 42,43,58,59 .  
Similarly, this variant also segregates more in the unaffected samples in the case control 
study.  The variant rs2295190 in SYNE1 has been previously identified to increase the 
risk of ovarian cancer 60 .  Similarly, this variant also segregates more in the breast 
cancer affected samples than in the case control.  These results show that our case 
control sample size of 54 is large enough to identify previously identified risk modifying 










Figure 9. Probable biological variants previously identified to associate with 
breast or ovarian cancer risk.  All variants that segregated with a p≤0.15 and predicted 
damaging by PolyPhen2 (PP2) or SIFT were manually searched in PubMed to find 
published association of the variant with breast or ovarian cancer.  The variant 
rs8100241 in ANKLE1 was previously identified by CIMBA to decrease the risk of breast 
cancer in BRCA1 mutation carriers.  The variant rs2295190 in SYNE1 has been 
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2.3.1.3.2 Newly identified breast and/or risk modifying variants   
Next, we attempted to identify new variants that modified the risk of breast cancer in 
BRCA1 affected carriers.  To decrease the chance of false positive variants, we set both 
statistical and biological filters as follows: 
1. The variants are predicted damaging by both PolyPhen2 and SIFT.  
2. The variants segregate with the statistical significances of P<0.05.   
3. Ingenuity pathway analysis link the affected gene to cancer  
4. There is a publication in PubMed that gives evidence that the affected gene is a 
known or a predicted tumor suppressor/oncogene.   
5. The amino acid change is in a known functional domain or odds ratio is <0.05 or 
>20 or the affected gene has a protein-protein interaction with a high-medium 
penetrance breast cancer predisposition gene. 
The variant ANLN_rs3735400, SIPA1L2_rs1547742 and MTHFSD_rs3751800 met all 
five criteria 61-66 (Figure 10).  These new and previously identified risk modifiers were 
then verified with Sanger sequencing and the odds ratios per allele was calculated 
(Table 10).  After Sanger sequencing, all five variants passed all biological and statistical 
filters.   
2.3.1.4 Cohort study to calculate the cumulative risk of the candidate genetic 
modifiers 
I then calculated if these variants changed the cumulative risk of developing breast 
cancer.  To answer this question, the five variants were analyzed further in a more 
statistically robust cohort study.   
  




Figure 10. Probable biological variants newly identified to associate with breast 
cancer risk.  All variants that segregated with a P<0.05 and predicted damaging by 
PolyPhen2 (PP2) and SIFT were searched in both Ingenuity pathway analysis (IPA) and 
PubMed for evidence that they affect known/predicted oncogene or tumor suppressors.  
These variants must also 1) cause an amino acid change in a known functional domain, 
2) have an odds ratio <0.05 or >20, or 3) the affected gene must have a protein-protein 
interaction with a high-medium penetrance breast cancer predisposition gene. 
The variants ANLN_rs3735400, SIPA1L2_rs1547742 and MTHFSD_rs3751800 passed 
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MAF* AA change 
Functional 
Domain OR 95% Cl P 
rs2295190 SYNE1 9 (16.7) 4 (7.4) 17.5 L-M KASH 2.87 0.760-10.865 0.119 
rs8100241 ANKLE1 17 (31.5) 31 (57.4) 45.5 G-A - 0.37 0.170-0.808 0.013 
rs3735400 ANLN 2 (3.7) 11 (20.4) 11.3 S-W NLS 0.15 0.033-0.748 0.020 
rs1547742 SIPA1L2 0 (0) 8 (14.8) 9.7 S-L - 0.05 0.003-0.931 0.045 
rs3751800 MTHFSD 3 (5.6) 11(20.4) 10.1 R-C - 0.24 0.063-0.917 0.037 
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In this cohort study, ~150 BRCA1 mutation carriers (16 unaffected and 80-91 breast 
cancer affected), were genotyped by Sanger sequencing and the Cox regression model 
was used to calculate the cumulative risk.  These new BRCA1 mutation carriers were 
selected based on the BRCA1 mutated status.   
After the cumulative risks were calculated, it was shown that all five variants statistically 
modify the risk of breast cancer in these BRCA1 mutation carriers.  SYNE1_rs2295190 
was the only variant to increase the risk of developing breast cancer in BRCA1 mutation 
carriers (HR 1.66, CI 1.05-2.63, P=0.031) (Figure 11).  ANKLE1_rs8100241, which was 
shown to decrease the risk of developing breast cancer in the CIMBA studies also 
decrease the risk of breast cancer in BRCA1 mutation carriers (HR 0.64, CI 0.5-0.099, 
P=0.046) (Figure 12).  The variants in ANLN_rs3735400 (HR 0.56, CI 0.34-0.93, 
P=0.025) (Figure 13), SIPA1L2_rs1547742 (HR 0.464, CI 0.28-0.77, P=0.003) (Figure 
14), and MTHFSD_rs3751800 (HR 0.28, CI 0.14-0.58, P=0.0006) (Figure 15) all 
decreased the risk of developing breast cancer in BRCA1 mutation carriers.   
2.3.2 Functional study  
As previously stated, candidate variants must be predicted damaging by variant 
prediction software as well as affect a gene known or predicted to be a tumor suppressor 
or oncogene.  The goal of these functional studies is to show evidence that these 
predictions were accurate.  To show evidence that the affected genes are oncogenes or 
tumor suppressors, we made knockdown cell lines and measured the cellular growth 
rate.  It is hypothesized that if the affected gene is an oncogene, the knockdown cell line 
will have a decreased growth rate in comparison to the control cell line.  Furthermore, it 
is also hypothesized that if the affected gene is a tumor suppressor, the knockdown cell 
line will have an increased growth rate in comparison to the control cell line.  
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Genotype Unaffected (%) Breast Cancer (%) HapMap % HR 95% Cl P 
CC 38 (86.4) 77 (74.8) 70.0 1.00   
CA 6 (13.6) 26 (25.2) 25.0 1.66 1.05-2.63 0.031 
AA 0 2 (1.9) 5.0 2.23 0.51-9.72 0.285 
Total 44 105     
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Genotype Unaffected (%) Breast Cancer (%) HapMap % HR 95% Cl P 
GG 9 (20.5) 34 (32.4) 32.1 1.00   
GA 25 (56.8) 53 (50.5) 44.6 0.64 0.41-0.99 0.046 
AA 10 (22.7) 18 (17.1) 23.2 0.59 0.33-1.05 0.074 
Total 44 105     
 
Figure 12. ANKLE1_rs8100241 cumulative risk of breast cancer 
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Genotype Unaffected (%) Breast Cancer (%) HapMap % HR 95% Cl P 
CC 29 (65.9) 93 (83.0) 81.4 1.00   
CG 15 (34.1) 19 (17.0) 15.3 0.56 0.34-0.93 0.025 
Total 44 112     
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Genotype Unaffected (%) Breast Cancer (%) HapMap % HR 95% Cl P 
CC 30 (68.2) 92 (82.9) 79.6 1.00   
CT 14 (31.8) 18 (16.2) 18.6 0.464 0.28-0.77 0.003 
TT 0 (0) 1 (.9) 1.8 2.000 0.25-16.09 0.515 
Total 44 111     
 
Figure 14. SIPA1L2_rs1547742 cumulative risk of breast cancer 
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Genotype Unaffected (%) Breast Cancer (%) HapMap % HR 95% Cl P 
CC 29 (65.9) 100 (91.7) 71.2 1.00   
CT 15 (34.1) 8 (7.3) 27.9 0.28 0.14-0.58 0.0006 
TT 0 (0) 1 (.9) 0.9 1.54 0.20-12.01 0.682 
Total 44 109     
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 To show evidence that the predicted damaging variant is altering the function of the 
affected gene, the function of the native allele and candidate modifier variant will be 
measured in vitro.  Because more specific experiments can be designed if a damaging 
variant is affecting a known functional domain, only candidate modifiers in known 
functional domains were analyzed.  It is hypothesized that if the predicted damaged 
variant is in a functional domain, this affected domain will be altered functionally.   
While there is statistical evidence to show these five variants change the risk of 
developing breast cancer in BRCA1 mutation carriers, it is unclear whether these 
variants affect pre- or post-transformed breast cells.  Because post-transformed cell 
lines with known BRCA1 mutations are more established than pre-transformed breast 
epithelial cell lines, these affected genes would be analyzed in post-transformed breast 
cancer cell lines.  Both HCC1937 and MCF7 have mutations in BRCA1.  HCC1937 has 
a homozygote BRCA1 mutation genotype and is a basal-like ER/PR- normal Her2/neu 
subtype.  MCF7 has a heterozygote null BRCA1 genotype and is an ER/PR+ normal 
Her2/neu luminal subtype.   
Three criteria were set for the selection of candidate modifiers for functional studies. 
1. The variants must be found to modify the risk of breast cancer in the cohort study 
with statistical significant P<0.05.   
2. The affected gene must be expressed in either MCF7 or HCC1937 cells. 
3. The variant must be in a functional domain. 
Variants found to modify the risk of breast cancer in the cohort study with statistical 
significant (P<0.05) are ANLN_rs3735400, SIPA1L2_rs1547742, MTHFSD_rs3751800, 
SYNE1_rs2295190 and ANKLE1_rs8100241.  To investigate the gene expression in 
these two cell lines, RNA-seq data from both HCC1937 and MCF7 was downloaded 
from the cancer genomics hub.  The only candidate gene not expressed in either cell line 
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was ANKLE1.  Similarly, it has been previously shown that ANKLE1 is not expressed in 
breast cell lines 67 .  Finally, two candidate modifiers, ANLN_rs3735400 and 
SYNE1_rs2295190 were in known functional domains (Figure 16).  ANLN_rs3735400 is 
in a Nucleus Localization Sequence (NLS) and an mDia2-binding domain while 
SYNE1_rs2295190 is in a KASH domain important for nuclear membrane localization 
54,68 .   
2.3.2.1 ANLN 
2.3.2.1.1 Anillin and its role during cytokinesis  
Actin-binding protein Anillin (ANLN) was first identified in Drosophila and plays important 
roles in cytokinesis 69 .  Anillin is localized to the nucleus during interphase and relocates 
to the cortex after the nuclear envelope degrade.  It then localizes to the equatorial 
cortex in anaphase and at the cleavage furrow during telophase 70 .  The ingression of 
the cleavage furrow separates daughter cells at the end of mitosis (Figure 17).  This 
furrow ingression is driven by the assembly and contraction of actomyosin filaments, 
forming a contractile ring.  Cytoskeletal protein Anillin has a pivotal role in the 
organization of the network of cytoskeletal proteins at the cleavage furrow.  This network 
of cytoskeletal proteins acts as a scaffold connecting actomyosin filaments to the plasma  
membrane 70-73 .   
2.3.2.1.2 Anillin functional domains 
Human Anillin is comprised of four functional domains: Myosin-2-binding domain, Actin-
binding domain, RhoA-binding domain and the pleckstrin-homology (PH) domain.  Anillin 
also includes three other secondary structures: destruction box (Dbox), nuclear 
socialization signal (NLS), and Src-homology-3-binding consensus sequences (SH3).  
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Figure 16.  Candidate modifiers of breast cancer risk chosen for functional 
studies.  Three criteria were set for the selection of candidate modifiers for functional 
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Figure 17.  Localization of Anillin during the cell cycle in mammals.  Anillin protein 
is depicted in red, chromosomes in black and microtubules, centrosomes, and spindle-
pole bodies in blue 70 .   
  
1075Anillin-related proteins in cytokinesis
kinase homologue Plo1p (Ohkura et al., 1995), which acts as a
positive cue because it promotes Mid1p nuclear export at mitotic
entry, increasing its concentration at the equatorial cortex (Bahler
et al., 1998). plo1 and mid1 interact genetically and physically
(Table 1) and Mid1p is phosphorylated during mitosis, but it is
unclear whether Plo1p directly phosphorylates Mid1p (Bahler
et al., 1998; Sohrmann et al., 1996). Computer simulations indicate
that nuclear export per se cannot explain the localization of Mid1p
to the medial region; instead, inhibitory mechanisms must also
prevent it spreading towards the cell ends (Padte et al., 2006). This
second inhibitory pathway involves Pom1p, a DYRK-family kinase
that controls polarized cell growth in fission yeast (Bahler and
Pringle, 1998). In pom1 mutants, Mid1p cortical distribution
spreads from the medial region to the non-growing end;
consequently, the division site also shifts towards the same non-
growing tip (Celton-Morizur et al., 2006; Padte et al., 2006). Thus,
Pom1p excludes Mid1p from the non-growing end and cooperates
with the Plo1p-dependent export of Mid1p from the nucleus to
localize Mid1p in a medial cortical band. Another, as-yet-
unidentified signalling pathway must also prevent Mid1p from
associating with the growing end.
Function of Anillin-related proteins
Drosophila
The function of Anillin in Drosophila has been elucidated by the
study of anillin (also known as scraps) mutants and by RNAi-
dependent Anillin depletion in both cultured cells and flies. The
actomyosin ring is assembled normally in early telophase cells after
anillin RNAi, but it becomes severely disorganized in late telophase,
exhibiting aberrant F-actin accumulation and the formation of
numerous membrane blebs; this ultimately leads to a late failure of
cytokinesis (Echard et al., 2004; Somma et al., 2002). Thus, Anillin
is not required for F-actin accumulation at the furrow but rather for
proper organization of the contractile ring. Similarly, recruitment
of myosin II to the cleavage site does not require Anillin (Straight
et al., 2005), although a recent time-lapse study reported abnormal
furrow oscillations along the spindle axis in Anillin-depleted cells,
which was followed by mislocalization of the MRLC (Hickson and
O’Farrell, 2008). However, this unstable-furrow phenotype was not
observed in previous studies that used fixed preparations (Somma
et al., 2002; Straight et al., 2005) or in time-lapse analysis using a
similar cell line expressing a tubulin-GFP-encoding transgene
(Echard et al., 2004); the reasons for this discrepancy are unclear.
Analysis of anillin mutant animals demonstrated that Anillin is
essential for viability and functions in cytokinesis, for pole-cell
formation and for cellularization in Drosophila embryos. Indeed,
Anillin concentrates at the leading edge of the membrane
invaginations that are responsible for cellularization during early
embryogenesis, which are enriched in both F-actin and myosin II.
Furthermore, the localization of myosin II and septins is disrupted
in anillin mutant embryos (Field et al., 2005; Thomas and
Wieschaus, 2004). Anillin is also essential for the recruitment of
the septins Peanut and Septin 2 to the furrow in cultured Drosophila
cells. These proteins often mislocalize on central-spindle
microtubules following anillin RNAi, which suggests that septins
travel along spindle microtubules to reach the cortex where they
interact with Anillin (D’Avino et al., 2008). By contrast, septins
are not required for proper Anillin localization at the cleavage furrow
in cultured cells or embryos (Adam et al., 2000; D’Avino et al.,
2008). Finally, although Anillin is not required for RacGAP50C
localization to the spindle midzone (D’Avino et al., 2008; Gregory
et al., 2008), it does seem to be necessary for RacGAP50C
accumulation at the cortex in larval brain cells (Gregory et al., 2008).
Altogether, these data indicate that Anillin is essential for the proper
organization of actomyosin contractile structures, but not their initial
assembly or contractile activity, during both cytokinesis and
embryonic cellularization.
C. elegans
Of the three Anillin-related proteins in C. elegans (ANI-1, ANI-2
and ANI-3), only ANI-1 appears to be important for contractile-ring
formation (Maddox et al., 2005). RNAi of ani-3 does not lead to any
abnormalities, either alone or in combination with depletion of ANI-
1 or ANI-2. ANI-2 localizes to the hermaphrodite gonad and is
required for the structural organization of this organ. ani-1 knockdown
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Fig. 3. Localization of Anillin-related proteins during the cell cycle in fission yeast, Drosophila and vertebrates. The distribution of Anillin-related proteins is
depicted in red, nuclei in grey, chromosomes in black, and microtubules, centrosomes and spindle-pole bodies in blue. ANI-1 also accumulates at the cleavage
furrows in C. elegans embryos, but its distribution in cycling cells has not been described.
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The destruction box (Dbox) domain of Anillin binds to cadherin 1, type 1 (CDH1) and 
anaphase prompting complex (APC), which is an ubiquitin protein ligase that 
ubiquitinates Anillin, promoting its degradation during late mitosis/G1 74 .  The nuclear 
socialization signal (NLS) of Anillin binds the protein Important b2, which shuttles Anillin 
from the cytoplasm to the nucleus during interphase 54 .  The Src-homology-3-binding 
consensus sequence (SH3) regulates the active state of adaptor proteins and increase 
the substrate specificity of some tyrosine kinases.  The Myosin-2 binding domain of 
Anillin binds myosin-2, which is responsible for actin-based motility 73 .  The Actin-binding 
domain of Anillin binds actin, which is a protein that forms microfilaments 75 .  The RhoA 
domain of Anillin binds the gene Ras Homolog Family Member A (RhoA), which is a 
member of the Rho family of small GTPases 72 .  The pleckstrin-homolgy (PH) domain of 
Anillin has been shown to bind septins at the plasma membrane 76  (Figure 18). 
2.3.2.1.3 Anillin role in Cancer 
Anillin has been found to be overexpressed in many different tumors.  Furthermore, 
Anillin expression has also been found to be a prognostic biomarker for cancer 61 .  Other 
studies have found that high nuclear fraction of ANLN was associated with large tumor 
size, high histological grade, high proliferation and estrogen receptor (ER) negativity 77 .   
Recently it has been shown that stable Anillin knockdown breast cancer cell lines MDA-
MB-231 and ZR-75-30 have decreased growth rates.  These knockdown cells also have 
increased percentage of cells in G2/M phase 62 .  This growth rate defect in breast 
cancer cell lines give evidence that Anillin is not only a cancer biomarker but also an 
oncogene in breast cancer. 
2.3.2.1.4 ANLN knockdown 
While both MDA-MB-231 and ZR-75-30 have decreased growth rates after ANLN 
expression is decreased, these cell lines have normal BRCA1 expression.   




Figure 18.  Secondary structures of Anillin protein in humans.  Variant rs3735400 is 
located in the N-terminal region of Anillin and causes a change from serine to tryptophan 
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To test if breast cancer cell lines with BRCA1 mutations are affected by decreased 
expression of ANLN, shRNA specific for ANLN was infected into both MCF7 and 
HCC1937 cell lines.  As stated previously, HCC1937 has a homozygote BRCA1 
mutation genotype and is a basal-like ER/PR- normal Her2/neu subtype cell line while 
MCF7 has a heterozygote null BRCA1 genotype and is a luminal subtype cell line.  
HCC1937 cells infected with shRNA_ANLN are not viable.  All infected HCC1937 cells 
die within two days.  This infection was repeated three times with similar results.  
However, a stable ANLN knockdown in MCF7 showed a decreased growth rate in 
comparison to the scrambled_shRNA infected MCF7 cells (Figure 19).  This growth rate 
defect is similar to the effects of shRNA_ANLN in both MDA-MB-231 and ZR-75-30 
cells.  These results show that BRCA1 mutated cell lines are equally sensitive, if not 
more sensitive, to the decreased expression of ANLN.  Furthermore, this gives evidence 
that Anillin is a true oncogene. 
2.3.2.1.5 Variant rs3735400 affects the function of Anillin 
2.3.2.1.5.1 Nuclear localization 
The variant rs3735400 is a nonsynonymous mutation that causes a serine to tryptophan 
mutation of amino acid 65 in Anillin.  This variant is localized upstream of the NLS of 
Anillin (Figure 20).  To investigate if the variant rs375400 alters the ability of Anillin to 
localize to the nucleus, we transfected a N-terminal GFP-tagged Anillin construct into 
HeLa cells (Figure 21).  We found that Anillin with the variant rs3735400 had defected 
nuclear localization in comparison to the wild type Anillin (Figure 22).  While the function 
of Anillin in the nucleus is unknown, it has been shown that Anillin with a mutated NLS 
maintain the ability to rescue the bi-nucleated phenotype caused by an Anillin  
knockdown 54 .   
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Figure 19. Growth rate measurement of MCF7 infected shRNA_ANLN cells. 
Knockdown of Anillin in MCF7 cells causes the growth rate to decrease in comparison to 
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Figure 20.  N-terminus of Anillin has conserved NLS across different vertebrate 
species.  The variant ANLN_rs3735400 affects the amino acid three amino acids 



































upon the expression of either GFP-anillin or the non-importin
!2-binding mutant, GFP-anillin(K68A/K69A/R70A) (Fig. 6, B
and C), indicating that importin !2 binding does not regulate
anillin’s cytokinetic function.
Cytosolic Accumulation of Anillin Disrupts Cell Shape—Suc-
cessful cell division requires that cytokinesis takes place at the
end of mitosis, after the completion of chromosome segrega-
tion. Given anillin’s crucial role in linking the cell membrane
with the actin and septin cytoskeletons at the cytokinetic fur-
row, we postulated that the presence of anillin in the cytoplasm
during interphase would disrupt the cellular cytoskeleton, thus
necessitating that anillin be kept inactive by sequestration in
the nucleus during interphase. To test this model, we tran-
siently overexpressed GFP-anillin or GFP-anillin(K68A/K69A/
R70A) in HeLa cells. When overexpressed, GFP-anillin still
localized to the nucleus, and the cytosolic actin organization
and cell shape were similar to cells not expressing GFP-anillin
(Fig. 7A). In contrast, in 93 ! 3.5% of cells overexpressing GFP-
FIGURE 2. N terminus of anillin has distinct conserved regions across different vertebrate species and binds to importin !2 in a Ran-dependent
manner. A, alignment of the first 100 amino acids of anillin in different vertebrate species. B, consensus motifs for different classes of nuclear localization
sequences. C, comparison of the anillin bPY motif to other bPY motifs. D, recombinant His6-tagged importin " and !1 or !2 were incubated with a MBP-
anillin(1–151) fusion protein. The MBP-anillin fusion protein was re-isolated on amylose beads, and co-purifying His6-tagged proteins were detected by
SDS-PAGE and Western blotting. E, His6 importin !2-MBP-anillin binding reaction described in A was repeated in the presence and absence of recombinant
GST-RanGTP. Alignment of the anillin importin !2-binding motif with other known importin !2-binding motifs.
Nuclear Targeting of Anillin

























Figure 21.  Anillin constructs transfected into HeLa cells.  To analyze the effects of 
ANLN_rs3735400 on Anillin nuclear localization, a full length GFP tagged Anillin_wt and 
Anillin_(S65W) were transfected into HeLa cells.  Both proteins are able to localize to the 






importin !2, thereby allowing it to specifically out-compete
cargo from importin !2 (27, 28). When expressed in cells as
an MBP fusion protein, M9M-MBP significantly reduced the
level of GFP-anillin localized to the nucleus compared with
expressing MBP alone (Fig. 4B). Therefore, both in vitro and
in vivo data indicate that importin !2 targets anillin to the
nucleus.
Importin !2 Binds to a Unique Site on Anillin—The binding
of NTRs to mitotic proteins can regulate the function of a
mitotic protein, for instance by displacing downstream targets
(29 –32), and can also serve to spatially constrain a protein’s
activity within the cell (29, 30, 33, 34). Because the N-terminal
region of anillin mediates its interaction with CD2AP (26) and
mDia2 (35), we tested whether importin !2 competed with
either protein for binding to anillin in vitro. Increasing concen-
trations of importin !2 had no effect on the binding of CD2AP
or mDia2 to anillin (Fig. 5, A and B), suggesting that importin
!2, CD2AP, and mDia2 have distinct and nonoverlapping anil-
lin-binding sites.
Importin !2 Binding Is Not Required for Anillin’s Role in
Cytokinesis—We next assessed whether importin !2 binding
could regulate anillin’s function in cytokinesis by monitoring
cytokinesis in HeLa cells expressing anillin(K68A/K69A/
R70A). A stable HeLa cell line expressing anillin(K68A/K69A/
R70A) under the control of a tet repressor was generated, and
culture conditions developed to induce the anillin(K68A/
K69A/R70A) transgene expression at a similar level to endoge-
nous anillin (Fig. 6A). Endogenous anillin expression was then
suppressed by siRNA targeted to the 3!UTR of the endogenous
anillin mRNA. In the absence of transgene expression, deple-
tion of anillin resulted in the accumulation of bi-nucleate cells
(81 " 7.1% of the total cells, Fig. 6, B and C), a phenotype
characteristic of cytokinetic failure and consistent with previ-
ous results (17, 19, 36). The bi-nucleate phenotype was rescued
FIGURE 1. Nuclear localization sequence of anillin lies in the first 91 amino acids. A, schematic of the domain organization of anillin and the GFP-anillin
fusion proteins expressed in HeLa cells shown in B. FL, full-length anillin sequence; wt, wild type sequence. B, micrographs of HeLa cells transiently expressing
different GFP-anillin fusion proteins described in A. C, quantitation of the ratio of GFP fluorescence between the nuclear and cytoplasmic compartments for
HeLa cells expressing different GFP-anillin fusion proteins described in A and B. Bar, 5 "m. Myo, myosin; Act, actin; AH, anillin homology domain; PH, pleckstrin
homology domain.
Nuclear Targeting of Anillin














importin !2, thereby allowing it to specifically out-compete
cargo from importin !2 (27, 28). When expressed in cells as
an MBP fusion protein, M9M-MBP significantly reduced the
level of GFP-anillin localized to the nucleus compared with
expressing MBP alone (Fig. 4B). Therefore, both in vitro and
in vivo data indicate that importin !2 targets anillin to the
nucleus.
Importin !2 Binds to a Unique Site on Anillin—The binding
of NTRs to mitotic proteins can regulate the function of a
mitotic protein, for instance by displacing downstream targets
(29 –32), and can also serve to spatially constrain a protein’s
activity within the cell (29, 30, 33, 34). Because the N-terminal
region of anillin mediates its interaction with CD2AP (26) and
mDia2 (35), we tested whether importin !2 competed with
either protein for binding to anillin in vitro. Increasing concen-
trations of importin !2 had no effect on the binding of CD2AP
or mDia2 to anillin (Fig. 5, A and B), suggesting that importin
!2, CD2AP, and mDia2 have distinct and nonoverlapping anil-
lin-binding sites.
Importin !2 Binding Is Not Required for Anillin’s Role in
Cytokinesis—We next assessed whether importin !2 binding
could regulate anillin’s function in cytokinesis by monitoring
cytokinesis in HeLa cells expressing anillin(K68A/K69A/
R70A). A stable HeLa cell line expressing anillin(K68A/K69A/
R70A) under the control of a tet repressor was generated, and
culture conditions developed to induce the anillin(K68A/
K69A/R70A) transgene expression at a similar level to endoge-
nous anillin (Fig. 6A). Endogenous anillin expression was then
suppressed by siRNA targeted to the 3!UTR of the endogenous
anillin mRNA. In the absence of transgene expression, deple-
tion of anillin resulted in the accumulation of bi-nucleate cells
(81 " 7.1% of the total cells, Fig. 6, B and C), a phenotype
characteristic of cytokinetic failure and consistent with previ-
ous results (17, 19, 36). The bi-nucleate phenotype was rescued
FIGURE 1. Nuclear localization sequence of anillin lies in the first 91 amino acids. A, schematic of the domain organization of anillin and the GFP-anillin
fusion proteins expressed in HeLa cells shown in B. FL, full-length anillin sequence; wt, wild type sequence. B, micrographs of HeLa cells transiently expressing
different GFP-anillin fusion proteins described in A. C, quantitation of the ratio of GFP fluorescence between the nuclear and cytoplasmic compartments for
H La cells expressi g different GFP-anillin fusio proteins described in A and B. Bar, 5 "m. Myo, myosin; Act, actin; AH, anillin homology d mai ; PH, pleckstrin
homology domain.
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Figure 22.  ANLN_rs3735400 affects the nuclear localization of Anillin.  Different 
GFP-Anillin fusion proteins in HeLa cells showing a ratio change of GFP fluorescence 
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2.3.2.1.5.2 Knockdown growth rate rescue 
Next, we investigated whether ANLN with the variant rs3735400 can rescue the growth 
rate phenotype caused by an Anillin knockdown in MCF7 cells.  It has been shown that 
the first 115 amino acids of Anillin is required for the proper localization of mDia2 to the 
cleavage furrow 78 .  Furthermore, truncated Anillin without the first 115 amino acids 
abolishes the ability of Anillin to rescue the bi-nucleated phenotype caused by an Anillin 
knockdown 78 .  Because rs3735400 affects an amino acid within the first 115 amino 
acids (ANLN_S65W), it was hypothesized that this variant will disrupt the ability of Anillin 
to rescue the growth rate defect caused by an infection of shRNA_Anillin in MCF7 cells.  
Growth rate of iInfected shRNA_ANLN cells rescued with transfected ANLN_wt was 
similar to cells with endogenous levels of Anillin protein.  However, infected 
shRNA_ANLN cells transfected with ANLN_(S65W) showed similar growth rates to cells 
that were infected with shRNA_ANLN and transfected with an empty vector (Figure 23).  
This result suggests that the variant rs3735400 may alter the function of ANLN and its 
ability to regulate cellular proliferation. 
2.3.2.2 SYNE1 
2.3.2.2.1 SYNE1 and its role in nuclear membrane stability 
Nesprin-1 (SYNE1) belongs to a family of spectrin-repeat proteins.  Alternate initiation 
and splicing of SYNE1 generate multiple isoforms that vary greatly in size and function.  
Giant isoform Nesprin-1 is composed of a spectrin-repeat rod domain linked to a  
C-terminal transmembrane KASH (Klarsicht-ANC-SYNE-homology) domain, which 
mediates nuclear membrane localization, and N-terminal alpha-actinin-type actin-binding 
domain (ABD) 79 .  Nesprin-1 is an essential component of the nuclear envelope and is 
part of the LINC (linker of nucleoskeleton and cytoskeletion) complex.   




Figure 23.  ANLN_rs3735400 inhibits Anillin ability to rescue the ANLN 
knockdown.  The ANLN knockdown could be rescued with ANLN_wt.  ANLN_(S65W) 
protein was unable to rescue the knockdown growth rate defect and had a similar rate to 
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Disruption of the nuclear-cytoskeleton connections affects the stability, size, and shape 
of the nucleus and alters cell migration and mechanical properties of the cell  80-83 .   
2.3.2.2.2 SYNE1 and cancer 
Downregulation of Drop1, an N-terminal isoform of Nesprin-1 has been observed in early 
tumor stages in a wide range of human carcinomas 84 .  Furthermore, data from TCGA 
and other publications have shown that SYNE1 is frequently mutated in both breast and 
colorectal cancer 85 .  It has also been reported that Nesprin-1 has a role in DNA damage 
response and DNA repair and mismatch repair pathways, which are determinants of 
genetic instability in cancer.  It was observed that human foreskin cells (HFF1) 
transfected with siRNA_SYNE1 had a larger percentage of gamma-H2AX positive cells 
than cells with endogenous levels of SYNE1.  Gamma-H2AX is a biomarker for DNA 
double-strand breaks 86 .  These siRNA_SYNE1 HFF1 cells also have defects in size 
and shape of the nucleus.  It is hypothesized that this genomic instability is occurring in 
these knockdown cells due to a combination of alterations in the DNA damage response 
and mismatch repair pathways and increased physical stress of the nuclear membrane.  
This increase in DNA double-strand breaks is especially interesting to this study 
because a critical function of BRCA1 is to repair DNA double-strand breaks 87 .  
The variant SYNE1_rs2295190 has previously been associated with an increased risk of 
developing invasive epithelial ovarian cancer 60 .  The result of the cohort study also 
associated rs2295190 with an increased risk of developing breast cancer in BRCA1 
mutation carriers.  The mutation frequency in cancer, function in genomic stability, and 
association of the predicted damaging variant rs2295190 with an increase in breast and 
ovarian cancer risk gives evidence that SYNE1 is a tumor suppressor.   
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2.3.2.2.3 Knockdown SYNE1 
To investigate the role of SYNE1 in breast cancer, a stable shRNA_SYNE1 MCF7 cell 
line was made.  HCC1937 cells were not infected with SYNE1_shRNA because SYNE1 
is not expressed in this cell line. SYNE1 knockdown MCF7 cells have an increased 
growth rate in comparison to the Scrambled_shRNA infected MCF7 cells (Figure 24).  
This increased growth rate in MCF7 cells and the increased genomic instability in HFF1 
cells gives further functional evidence that SYNE1 is a tumor suppressor.   
2.3.2.2.4 Variant rs2295190 affects the function of Nesprin-1 
The variant rs2295190 is a nonsynonymous mutation that causes a leucine to 
methionine alteration of amino acid 8693 in Nesprin-1 (Figure 25).  This alteration is in 
the neck region of the KASH domain, which is the nuclear transmembrane domain of 
Nesprin-1 (Figure 26).  Because this amino acid is very conserved in multiple organisms 
and located near the nuclear transmembrane domain, we hypothesize that this variant is 
altering the ability of Nesprin-1 to localize to the nuclear membrane 55 .  To test this 
hypothesis, a N-terminal truncated N-terminal tagged GFP Nesprin-1 construct was used 
to investigate whether this variant can alter the ability of truncated Nesprin-1 to bind to 
the nuclear membrane (Figure 27).  As previously published, this construct with the 
native allele binds tightly around the nuclear membrane.  However, once the native 
amino acid was changed from a leucine to a methionine, the GFP-Nesprin-1_(L8693M) 
was dispersed throughout the cytoplasm and seemed to lose the ability to localize tightly 
to the nuclear membrane.  This localization alteration gives evidence that the variant 
rs2295190 can alter the function of the tumor suppressor Nesprin-1.  
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Figure 24. Growth rate measurement of MCF7 infected shRNA_SYNE1 cells. 
Knockdown of Nesprin-1 in MCF7 cells causes the growth rate to increase in 































Figure 25.  Secondary structures of Nesprin-1 protein in humans.  Nesprin-1 binds 
to the F-Actin and the nuclear membrane.  Variant rs2295190 is located in the C-
terminal nuclear transmembrane KASH domain of Nesprin-1 and causes a leucine to 
methionine amino acid change. 
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Figure 26.  C-terminus KASH domain of Nesprin-1 is conserved in different 
vertebrate species.  The variant SYNE1_rs2295190 affects an amino acid in the neck 
region of the KASH domain of Nesprin-1.  Mm, Mus musculus. Hs, Homo sapiens. 
  
5025Nuclear migration and anchorage
(Zhang et al., 2002). Like ANC-1, Msp-
300/nesprin contains a C-terminal KASH
domain and an N-terminal ABD, which
binds directly to F-actin in vitro and
decorates these filaments in vivo
(Rosenberg-Hasson et al., 1996; Volk,
1992). The region in between comprises a
series of spectrin repeats (SRs) (Fig. 2) –
three-helix bundles that can give proteins
length and elasticity and mediate protein
interactions, including homodimerization
(Djinovic-Carugo et al., 2002; Mislow et
al., 2002a). Interestingly, the repetitive
regions in ANC-1 are not related to SRs,
although they apparently have an
analogous function. Msp-300/nesprin
appears to be localized predominantly at
the NE in nurse cells and the oocyte, but
some also appears to be present in the cytoplasm (Yu et al.,
2006). Curiously, expression of a GFP-KASH domain fusion
protein does not have any obvious detrimental defects on the
position of the nuclei in these cells. This suggests that the
docking sites for Msp-300/nesprin, like those of Klarsicht, are
not limited at the NE.
During oogenesis in Drosophila, one of the cells in the egg
chamber becomes the oocyte; the other 15 become the
supporting polyploid nurse cells. Eventually, the nurse cells
‘dump’ their cytoplasmic contents into the oocyte through ring
canals and then undergo apoptosis (Spradling, 1993). The
positions of the nuclei are thought to be crucial during this
process because if they were to become detached they would
block the canals (Yu et al., 2006). Since actin structures are
important for nuclear anchorage in the nurse cells during
dumping (Guild et al., 1997), Yu et al. investigated whether
Msp-300/nesprin plays a role in this process by generating flies
carrying the Msp-300SZ-75 allele only in the germ line (these
flies are viable but do not contribute any wild-type Msp-
300/nesprin to the developing Msp-300SZ-75 egg chamber) (Yu
et al., 2006). Indeed, the egg chambers in these flies exhibit
defects in cytoplasmic dumping and nuclear positioning (Yu et
al., 2006) (Fig. 3B). Interestingly, they also have defective actin
structures, which suggests that Msp-300/nesprin also has a role
in actin organization (i.e. bundling and/or cross-linking), a role
attributed to other ABD-containing proteins (Winder and
Ayscough, 2005).
Interestingly, the Msp-300SZ-75 mutation is lethal, unlike
the deletion of ANC-1 in C. elegans. Larvae die because they
do not hatch from the chorion owing to the previously
mentioned defects in muscle attachment and contraction and
not nuclear anchorage defects (Rosenberg-Hasson et al.,
1996). By contrast, ANC-1 seems not to have crucial
functions besides those associated with nuclear and
mitochondrial anchorage.
The mammalian nesprins
The mammalian nesprins were originally identified in yeast
two-hybrid screens for binding partners of a tyrosine kinase of
the postsynaptic membrane in muscle (MuSK) (which yielded
nesprin-1) (Apel et al., 2000) and for the cytoskeletal cross-
linker protein plectin (which yielded nesprin-3) (Wilhelmsen
et al., 2005). Nesprin-1, originally named synaptic nuclear
envelope 1 (Syne-1) because of its presence at postsynaptic
nuclei of neuromuscular junctions (Apel et al., 2000), is
actually localized at the ONM of various cell types (Zhang et
al., 2001; Zhang et al., 2002). It is also referred to as myocyte
nuclear envelope 1 (Myne-1) (Mislow et al., 2002b) or enaptin
(Padmakumar et al., 2004). Nesprin-2 was identified in
database searches for sequences related to nesprin-1 or the !-
actinin ABD (Apel et al., 2000; Zhen et al., 2002). It is also
known as Syne-2 (Apel et al., 2000) or NUANCE (Zhen et al.,
2002).
Nesprin-1 and nesprin-2 are giant proteins of ~976 kDa and
~764 kDa, respectively (Zhang et al., 2002), and each contains
an N-terminal ABD (Padmakumar et al., 2004; Zhen et al.,
2002). Nesprin-3 is much smaller, ~110 kDa, and instead binds
to plectin at its N-terminus to connect it to IFs (Wiche, 1998;
Wilhelmsen et al., 2005). All three contain a series of
homologous SRs and a C-terminal KASH domain (Fig. 4). In
vitro binding assays and localization studies with the isolated
N-terminal regions indicate that the nesprins can indeed
interact with actin filaments and IFs (Fischer et al., 2004;
Padmakumar et al., 2004; Starr and Han, 2002; Wilhelmsen et
al., 2005; Zhen et al., 2002). Interestingly, plectin is ~500 kDa
and, when bound to nesprin-3, generates a bridge to IFs similar
in size to that which nesprin-1 and nesprin-2 provide for F-
actin. This suggests that it is important that there is a significant
distance between the nucleus and both the IF and F-actin
systems (Fig. 2).
Nuclear functions
In transgenic mice overexpressing the nesprin-1 KASH domain
in muscle cells, the nuclei do not aggregate beneath the
postsynaptic membrane, because endogenous nesprin-1 is
displaced from the NE (Grady et al., 2005). This implies that
the number of KASH-domain-binding sites at the NE is limited
(as is the case for ANC-1). How nesprin-1 tethers nuclei to the
postsynaptic membrane is not known, although an association
with actin structures or MuSK is probably required (Apel et
al., 2000; Grady et al., 2005). Surprisingly, although the nuclei
are not properly localized, the neuromuscular junction
functions normally.
Nesprin-1 and nesprin-2 exhibit a variety of isoforms
produced through the use of different translational initiation and
























Fig. 4. Alignment of KASH domains from various proteins. The amino acid residues present
in the predicted transmembrane regions are enclosed by red lines. The Zyg-12B KASH
domain sequence is used because the Zyg-12C KASH domain sequence in the database lacks
16 residues encompassing part of the neck and transmembrane regions. Dark green,
conserved amino acids; light green, amino acids with similar chemical properties in more
than half of the KASH domains. Mm, Mus musculus; Hs, Homo sapiens.
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Figure 27.  SYNE1-GFP tagged constructs transfected into HeLa cells.  To analyze 
the effects of SYNE1_rs2295190 on Nesptrin-1 nuclear membrane localization, a 
truncated GFP-tagged SYNE1_wt and SYNE1_(L8693M) were transfected into HeLa 
cells.  SYNE1_wt localized tightly to the nuclear membrane while SYNE1_(L8693M) was 
dispersed throughout the cytoplasm and seems to lose the ability to localize tightly to the 
nuclear membrane. SRs, spectrin repeats.  TM, transmembrane domain.   
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domain-containing proteins, Sun1 (accession number
AAH48156, mouse chromosomal locus 5G.2) and Sun2
(AAT90499, residing on chromosome 15). Mouse Sun1 and
Sun2 display 65% identity and 81% homology in their SUN
domain and 47%/39% identity and 63%/59% similarity to
the SUN domain of UNC-84, respectively. As Sun1 is more
closely related to UNC-84 than Sun2, Sun1 was chosen for the
current study. In addition, we used human Sun1, the closest
human orthologue to UNC-84, displaying 48% identity and
64% similarity to the SUN domain of UNC-84. Human Sun1
was originally identified as KIAA0810 by the Kazusa
DNA research institute (Kikuno et al., 2004;
http://www.kazusa.or.jp/huge/). Mouse Sun1 encodes a 100
kDa protein composed of 913 amino acids (Fig. 2A). It
contains three putative transmembrane domains (aa 358-383,
386-407 and 413-431) located approximately in the middle of
the protein, a predicted ZnF-C2H2 domain near the N-
terminus, and two predicted coiled-coil domains in the C-
terminus (aa 492-527 and 563-632). The last 175 residues are
highly homologous to C. elegans UNC-84 and S. pombe Sad1
forming the evolutionarily conserved SUN domain. The
domain structure of human Sun1 is identical to that of mouse,
except that it lacks the proposed zinc-finger motif. The region
between the transmembrane and the SUN domain was divided
into subdomains SD1 and SD2 for functional tests. SD1
contains the two coiled-coil regions whereas SD2 does not
display any known structural features
(Fig. 2A).
In yeast two-hybrid assays we
investigated the possible interaction
between the luminal domain of Nesprin-
1 and mouse Sun1. The last 30 amino
acids (luminal domain) of mouse
Nesprin-1 were fused in-frame to the
binding domain of Gal4 and were tested
for an interaction with five different C-
terminal Sun1 fusion constructs with
the activating domain of Gal4. These
included Sun1-C (C-terminus of Sun1),
Sun1-C∆SUN, which lacks the SUN
domain, Sun1-SUN composed solely of
the SUN domain, Sun1-SD1 and Sun1-
SD2 (Fig. 2B). Co-transformation of the
Journal of Cell Science 118 (15)
Fig. 1. The C-termini of Nesprins are conserved
and sufficient for NE localisation. (A) Alignment
(using MultiAlign) of the 30 amino acid luminal
domains of various KASH-domain NE proteins.
The green bar denotes the highly conserved C-
terminal prolines. (B) The tmNesprin-1, tmNesprin-
2, tmNesprin-2∆P (lacks the last four aa) and
dnNesprin-1 GFP fusion constructs used for the
experiments shown in C-N. LD, luminal domain;
SR, spectrin repeats; TM, transmembrane domain.
(C-K) Dominant-negative effect of tmNesprin-1,
tmNesprin-2 and dnNesprin-1 GFP fusions on the
endogenous Nesprin proteins. Transiently
transfected cells were fixed and subjected to
immunofluorescence using the monoclonal K20-
478 anti-Nesprin-2 and a rabbit polyclonal Nesprin-
1 antibody. These antibodies did not recognise
epitopes on the ectopically expressed polypeptides.
Note the nuclear rim staining of endogenous
Nesprin proteins in untransfected cells (arrowheads
in E,H,K) and the absence of Nesprin staining in
GFP-positive cells (arrows in E,H,K). (L-N)
Confocal images demonstrate a cytoplasmic (panel
L, arrows) and a diffuse nuclear staining pattern
(panel L, arrowhead) for GFP-Nesprin-2∆P, which
does not affect endogenous Nesprin-2 at the nuclear
envelope (arrowhead in M). The cell lines used are
indicated in the lower right-hand corner of the first
column of frames (C,F,I). DNA was stained with
DAPI. Images were obtained by confocal laser-
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2.4 Discussion  
2.4.1 Statistical association that common variants can modify the risk of breast 
cancer in BRCA1 mutation carriers 
Prior to this study, the only evidence that common variants could affect the risk of 
developing breast cancer in BRCA1 mutation carriers was from GWAS studies.  GWAS 
studies are purely based on statistical analysis and the variants identified are not 
selected based on biological plausibility.  There has been no published studies to 
functionally link the variants found in these GWAS studies to breast cancer.  The 
ultimate goal of this study was to identify variants that statistically change the risk of 
developing breast cancer in BRCA1 mutation carriers as well as provide functional 
evidence linking these variants to breast cancer development.   
To identify breast cancer risk variants, we sequenced 27 high risk and 27 low risk 
BRCA1 mutation carriers with exome next-generation sequencing.  We then applied 
multiple biological and statistical filters to identify variants that are linked both statically 
and functionally to breast cancer risk.   
The statistical association results identified five variants (ANKLE1_rs8100241, 
ANLN_rs3735400, SIPA1L2_rs1547742, MTHFSD_rs3751800 and SYNE1_rs2295190) 
that both modify the risk of breast cancer with statistical significant and are predicted to 
alter genes previously linked to cancer development.  A major concern for this study was 
that the case control sample size would be too small to accurately identify risk modifying 
variants.  Five of the variants identified in the case control study maintained statistical 
significance when re-examined in the more statistically powerful cohort study.  These 
results provide evidence that the case control study is powerful enough to identify risk 
modifying variants.  Furthermore, the variant ANKLE1_rs8100241 identified in the case 
control study was previously identified in other larger GWAS studies to modify the risk of 
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breast cancer in BRCA1 mutation carriers 42 .  The other four variants found in this study 
are newly identified BRCA1 mutation carrier genetic risk modifiers.  While all of the 
variants can be linked to cancer development, two of the five variants were chosen for 
further investigation with functional studies. 
2.4.2 Functional studies with ANLN_rs3735400 and SYNE1_rs2295190 
There were two aims for these functional studies. The first aim was to provide evidence 
that the affected gene could alter the growth rate of BRCA1 mutated breast cancer cells. 
The second aim was to provide evidence that the identified risk-modifying variants could 
alter the function of the affected gene.  Only two of the five variants, ANLN_rs3735400 
and SYNE1_rs2295190, were included in the functional studies because they were the 
only variants that affected a gene expressed in BRCA1 mutated breast cancer cells and 
are located in a known functional domain.  
2.4.2.1 ANLN_rs3735400 
It was shown that the predicted damaging variant ANLN_rs3735400 decreases the risk 
of breast cancer in BRCA1 mutation carriers.  Because damaging variants most 
commonly cause a loss of function genetic phenotype, it would be predicted that ANLN 
is an oncogene.  This is not the first time ANLN was predicted to be an oncogene. ANLN 
has previously been shown to be overexpressed in different types of cancer and is a 
biomarker for poor prognosis in breast cancer 61 . Furthermore, this functional study has 
shown that ANLN expression is linked positively to the proliferation rate of BRCA1 
mutation breast cancer cell lines, providing further evidence that ANLN is an oncogene.   
Next, we investigated whether ANLN_rs3735400 could alter the function of Anillin.  First, 
we showed that ANLN_rs3735400 could decrease the ability of Anillin to localize to the 
nucleus.  While the function of ANLN in the nucleus is currently unknown, it has been 
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hypothesized that Anillin is sequestered into the nucleus during interphase to control the 
Anillin ability to reorganize the actin filaments in a cell cycle dependent manner.  
Furthermore, the ability of ANLN to localize to the nucleus has been shown to be 
independent of its function during cytokinesis.   
The ability of ANLN_rs3735400 to rescue the growth rate caused by the shRNA_ANLN 
knockdown was investigated next.  It was shown that while ANLN_wt could fully rescue 
the phenotype caused by shRNA_ANLN, ANLN_(S65W) was unable to change the 
growth rate defect caused by shRNA_ANLN in MCF7 cells.  This was not suppressing 
as it has been shown that the N-terminal 115 amino acids of ANLN is critical to maintain 
Anillin ability to function during cytokinesis.  The N-terminal 115 amino acids were found 
to be critical for the localization and activation of the formin mDia2 to the cleavage 
furrow.  It has been shown that cells with altered mDia2 do not form F-actin required for 
transition through cytokinesis.  Because the variant ANLN_rs373540 is within this N-
terminal region, we hypothesize that this variant ANLN_(S65W) is inhibiting ANLN ability 
to interact with mDia2. 
2.4.2.2 SYNE1_rs2295190 
It was shown that the predicted damaging variant SYNE1_rs2295190 increases the risk 
of breast cancer in BRCA1 mutation carriers.  Because damaging variants most 
commonly cause a loss of function genetic phenotype, it would be predicted that SYNE1 
is a tumor suppressor.  This is not the first time SYNE1 has been predicted to be a tumor 
suppressor.  It has previously been shown that SYNE1_rs2295190 is associated with an 
increase in risk of ovarian cancer 60 .  In addition, SYNE1 has been shown to be 
frequently mutated in different types of cancer and loss of SYNE1 is known to increase 
genomic instability 68,84 .  Furthermore, this functional study has shown that decreasing 
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the expression of SYNE1 increases the proliferation rate of a BRCA1 mutation breast 
cancer cell line, providing more evidence that SYNE1 is a tumor suppressor.   
Next, it was investigated whether SYNE1_rs2295190 could alter the function of  
Nesprin-1. Giant Nesprin-1 has been shown to link the cytoskeleton to the 
nucleoskeleton by binding F-actin in both the cytosol and the nuclear membrane.  The 
variant SYNE1_rs2295190 changes a highly conserved amino acid leucine to a 
methionine in the neck region of the transmembrane KASH domain.  This study showed 
that the variant SYNE1_rs2295190 can alter the ability of Nesprin-1 to bind to the 
nuclear membrane.  It is hypothesized that this alteration of Nesprin-1 localization can 
affect the nucleoskeleton linkage, which has been shown to affect the function of both 
DNA repair and mismatch proteins.   
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Phasing the genome with NGS 
Information derived from genomic phasing can provide information on the genetic origin 
of disease and how DNA nucleotide alterations interact in cis.  However, current next-
generation sequencing techniques generate a single consensus sequence without 
distinguishing between variants on homologous chromosomes. Scientists and engineers 
are actively advancing genome phasing capabilities by redesigning methods of genomic 
library construction and improving the NGS platform technology so longer reads can be 
sequenced.  
The current experimental approaches used to phase the genome are too experimentally 
laborious to be commonly used.  The goal of my first project was to analyze a new 
experimentally non-laborious method of NGS library preparation hypothesized to 
increase the amount of phasing information derived from NGS data.  This new method 
involved cutting the genomic DNA with restriction enzymes instead of random shearing. 
It was shown that NGS libraries processed with restriction enzymes provide more 
phasing information than libraries made with random shearing.  However, there were 
some technical issues with the reads generated from restriction enzyme libraries.  First, 
libraries generated with a single restriction enzyme is only able to cover 40-50% of the 
exome.  With similar read depths, a NGS library made with random shearing covered 
about 75% of the exome.  However, exome coverage was greatly increased when NGS 
libraries were generated with a combination of four different restriction enzymes. While 
this method increases the exome coverage, the cost, time and quantity of genomic DNA 
required to process four libraries is more than that needed to make a single sonication 
derived NGS library.  
Another issue was that the reads from restriction enzyme libraries were difficult to map 
to the reference genome.  Furthermore, these difficulties might also be the reason why 
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many variants called from these reads were false variants.  These results are likely due 
to reads that are too small to be aligned accurately to the reference human genome.  
This technical issue and can be addressed by making changes to the methodology of 
restriction enzymes NGS library preparation.  Another option is to set more strict filters to 
remove lower quality reads before mapping to the reference genome.  However, it may 
make more fiscal sense to remove these reads before sequencing to save on Illumina 
sequencing running cost.  For now, it seems that the current gain-of-phasing information 
derived from restriction enzyme NGS libraries does not outweigh the technical issues 
with this method.   
Future directions for phasing the genome with NGS 
It is proposed that the ideal option to increase the number of phased variants while 
maintaining a low variant error rate is to modify the sonication method of shearing 
genomic DNA.  By pooling together two libraries, one library with the recommended 
fragment size and one library with a larger fragment size, the ability to construct larger 
contigs would increase and the sensitivity and specificity to call variants would be 
maintained.   
The NGS platform technology is currently the limiting factor in our ability to phase the 
genome with high-throughput sequencing.  However, as NGS platform technology 
improves, the ability to phase the genome will also increase (during my time as a PhD 
student, Illumina sequence lengths increased from 100bp to 150bp).  There are also 
talks of a fourth generation sequencing platform (Oxford Nanopore) that has no DNA 
fragment size limitations.  If this system works as described, it may be the solution to 
phasing the genome efficiently.  This technology will open up new fields of research that 
is currently underexplored.    
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Genetic modifiers of breast cancer risk of BRCA1 mutation carriers 
Risk of breast cancer is caused by a combination of environment and genetic modifiers. 
BRCA1 mutation carriers from familial breast cancer families have a wide range of risk 
(44-75%) of developing breast cancer by age 70 15 .  There are many known factors that 
can modify BRCA1 mutation carrier risk.   
Currently, there are limited risk assessments and treatment options for the intervention 
of breast cancer in BRCA1 mutation carriers, leading some carriers to undergo invasive 
mastectomy.  By identifying germline modifiers, physicians can provide better 
personalize cancer risk assessments to BRCA1 mutation carriers and researchers can 
potentially design new preventative therapies to lower the risk of cancer in these 
carriers. 
The majority of known modifying factors in BRCA1 mutation carriers are environmental.  
One reason for this is that the technology to perform GWAS studies has only been 
available for eleven years.  Furthermore, because information about genetic modifiers is 
from GWAS studies, which can only associate variants with changes of cancer risk, the 
variants that cause risk of breast cancer to change are currently unknown.  To date, 
there have been no studies to show that genetic variants can functionally changing the 
risk of breast cancer in BRCA1 mutation carriers.  The goal of this study was to identify 
variants that modify the risk of developing breast cancer in BRCA1 mutation carriers and 
provide functional evidence linking these variants to breast cancer development.   
This study is the first to identify new risk modifying variants (ANLN_rs3735400, 
SYNE1_rs2295190, SIPA1L2_rs1547742, MTHFSD_rs3751800, and 
ANKLE1_rs8100241) based on statistical and biological evidence.  While 
ANKLE1_rs8100241 was previously identified by GWAS studies to statistically decrease 
the risk of breast cancer in BRCA1 mutation carriers, there was no biological evidence 
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that this variant was functional important 59 .  SYNE1_rs2295190 was the only variant 
found to increase the risk of breast cancer in BRCA1 mutation carriers.  The variant 
SYNE1_rs2295190 has previously been shown to statistically increase the risk of 
ovarian cancer 60 .  Similar to the variant in ANKLE1, SYNE1_rs2295190 was previously 
identified without biological evidence that this variant was functional important.  The 
three newly identified risk modifying variants ANLN_rs3735400, SIPA1L2_rs1547742, 
and MTHFSD_rs3751800 were all shown to decrease the risk of breast cancer in 
BRCA1 mutation carriers.   
The variant MTHFSD_ rs3751800 was shown to have the greatest modifying effect of 
breast cancer risk in BRCA1 mutation carriers.  BRCA1 mutation carriers with the variant 
MTHFSD_ rs3751800 had a 70% lower risk of developing breast cancer than BRCA1 
mutation carriers without this variant.  Furthermore, this variant was also found to be the 
most statistically significant.  While this study has shown evidence that a variant in the 
gene MTHFSD is associated with lower breast cancer risk, there have been no studies 
to analyze the function of MTHFSD.  MTHFSD was previously identified in only one 
study, during a screen for genes that bind to p53 64 .  While there is evidence that 
MTHFSD and p53 bind, the consequence of MTHFSD binding to p53 remains unknown.   
The second goal of this study was to provide functional evidence that common variants 
can modify the risk of breast cancer in BRCA1 mutation carriers.  We decided to focus 
on the variants ANLN_rs3735400 and SYNE1_rs2295190 because they are both in 
functional domains and ANLN and SYNE1 are both expressed in cell lines with BRCA1 
mutations.  
While there is published evidence that ANLN is an oncogene and SYNE1 is a tumor 
suppressor, the function of these genes have not been investigated in a breast cancer 
cell line with BRCA1 mutations.  As expected, decreasing the expression levels of the 
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oncogene ANLN caused a decrease in growth rate of BRCA1 mutated breast cancer 
cells compared to cells with endogenous expression of ANLN.  It was also shown that 
decreasing the expression levels of the tumor suppressor SYNE1 increased the growth 
rate of BRCA1 mutation breast cancer cells in comparison to cells expressing 
endogenous levels of SYNE1.  These results provide functional evidence that both 
ANLN and SYNE1 can alter the proliferation rate of human breast cancer cells.  
Furthermore, there is now functional evidence that ANLN and SYNE1 can regulate the 
growth rate of BRCA1 mutation breast cancer cells.  These results provide evidence that 
ANLN and SYNE1 are good candidate genes that may be able to modify the risk of 
breast cancer in BRCA1 mutation carriers.   
Next, and perhaps more importantly, we investigated whether these variants could alter 
the function of the affected gene.  We first showed that the variant ANLN_rs3735400 
affected the proper nuclear localization of Anillin.  While the function of Anillin in the 
nucleus is unknown, previous studies have shown that the ability of Anillin to localize to 
the nucleus does not affect the ability of Anillin to rescue the knockdown phenotype. 
However, because the variant is also in the mDia2-binding domain of Anillin, which is 
critical for the ability of Anillin to rescue the knockdown phenotype, we investigated 
whether Anillin with ANLN_rs3735400 could rescue the knockdown phenotype.  It was 
shown that the full length Anillin with the ANLN_rs3735400 variant was unable to rescue 
the decreased growth rate caused by the shRNA_ANLN in MCF7 cells.  It has been 
shown that the N-terminal 115 amino acids of ANLN is critical to maintain Anillin function 
during cytokinesis 78 .  Because the variant ANLN_rs3735400 affects the N-terminal 65 
amino acid, we hypothesized that this variant ANLN_(S65W) is inhibiting ANLN ability to 
interact with mDia2. 
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These results provide evidence that the variant ANLN_rs3735400 can alter the ability of 
Anillin to drive proliferation.  While it remains unknown why Anillin with ANLN_rs3735400 
is unable to restore the proliferation rate, we hypothesize that ANLN_rs3735400 is 
affecting proper Anillin mDia2 binding during cytokinesis.  All of the functional results 
collected from this study provide evidence that BRCA1 mutation carriers with a mis-
functioning oncogene, Anillin, have a decreased risk of breast cancer in comparison to 
carriers with a fully functional Anillin oncogene.  
Next, we tested the ability of variant SYNE1_rs2295190 to disrupt the localization of a 
truncated Nesprin-1 to the nuclear membrane.  The major function of giant Nesprin-1 is 
to link the cytoskeleton to the nucleoskeleton by binding F-actin in the cytosol with the 
nuclear membrane.  An alteration of Nesprin-1 nuclear membrane localization can affect 
the nucleoskeleton linkage, which has been shown to affect the function of both DNA 
repair and mismatch proteins.  This disruption of DNA repair and mismatch proteins can 
increase genomic instability 68 .  It was shown that the variant SYNE1_rs2295190 greatly 
alters the ability of Nesprin-1 to bind to the nuclear membrane.  All of the functional 
results collected from this study give evidence that BRCA1 mutation carriers with a 
mutated tumor suppressor, Nesprin-1, have an increased risk of breast cancer in 
comparison to carriers with a fully functional tumor suppressor.   
Future directions for genetic modifiers of breast cancer risk of BRCA1 mutation 
carriers 
While three of the five variants (SIPA1L2_rs1547742, MTHFSD_rs3751800, and 
ANKLE1_rs8100241) were not functionally studied in this project, there is evidence that 
these genes are important in cancer development.   Because the function of MTHFSD, 
SIPA1L2 and ANKLE1 in vertebrates are unknown, we would propose to first analyze 
these genes with a proteomic approach.  Once the general function and binding partners 
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of these genes are known, one can start designing experiments to test whether these 
variants alter the function of the affected gene and if these genes are important for 
cancer development.  
The role of these five variants in the normal population should also be investigated.  
While these alleles may be beneficial in lowering the risk of breast cancer in the BRCA1 
population, they could have deleterious effects in the non-BRCA1 mutated population.  
Conversely, these common variants may lower the risk of cancer in the normal 
population.  One would expect that variants that decrease the risk of cancer may be 
selected for and should be found at a high frequency in the general population. 
However, this is only true if the variant is not causing a more severe or higher risk state 
than the benefit of the decreased cancer risk.   
It would also be interesting to calculate the frequency of these variants in populations 
with a high amount of BRCA1 mutation carriers.  If these variants only decrease risk of 
cancer in BRCA1 mutation carriers, one would expect that these variants would be more 
frequent in populations with a higher frequency of BRCA1 mutation carriers.   
Another important goal is to determine how different genetic modifiers affect each other 
and within the context of known environmental modifiers.  These types of studies can be 
difficult to perform because population size for these studies must increase greatly with 
the number of variables being accounted for.  However, knowledge gained from these 
studies would greatly improve the ability to accurately calculate risk assessment for 
BRCA1 mutation carriers.   
More studies should also be performed to investigate how the variant ANLN_rs3735400 
is affecting the function of Anillin.  Even though the variant ANLN_rs3735400 is located 
in the mDia2 binding domain and a truncated Anillin lacking the mDia2 domain has a 
similar inability to rescue a phenotype caused by an ANLN knockdown, it is unclear 
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whether ANLN_rs3735400 affects the ability of Anillin to bind to mDia2.  To investigate 
this, we propose using a protein complex immunoprecipitation pull-down assay.  
Furthermore, because ANLN_wt has been shown to co-localize with mDia2 at the cleave 
furrow during cytokinesis, we can also use immunofluorescence to investigate the 
localization of ANLN_(S65W) and mDia2 during cytokinesis.   These experiments would 
provide evidence on how ANLN_rs3735400 affects the function of Anillin.   
Further studies should also be performed to investigate the function of Anillin and 
Nesprin-1 in non-transformed breast epithelial cells.  We propose to use the non-
transformed breast epithelial cells MCF10a and MCF10a BRCA1-/- cells.  By inducing 
the variants with the Crisper/Cas9 system, we could change the specific nucleotide while 
maintaining the endogenous expression of the gene.  Results from these experiments 
will help clarify whether ANLN and SYNE1 are important for tumorigenesis or if they are 
only important in post-transformed breast cells.  
Results from this study would provide insight into whether manipulation of these genes 
or pathways could be used as cancer therapy and/or a cancer preventive therapy.  For 
example, if these studies provide new evidence that linkage between the cytoskeleton 
and nucleoskeleton influences breast cancer risk in BRCA1 mutation carriers, one could 
design preventative therapies to increase this linkage.  This type of therapy may be used 
to decrease the risk of breast cancer in BRCA1 mutation carriers.  Furthermore, if this 
linkage is important for genomic stability in all cell types, this therapy could be used to 
lower the risk of cancer in non-carriers as well.   
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Abstract Partner and localizer of BRCA2 (PALB2),
plays an important functional role in DNA damage repair.
Recent studies indicate that germline mutations in PALB2
predispose individuals to a high risk of developing familial
breast cancer. Therefore, comprehensive identification of
PALB2 germline mutations is potentially important for
understanding their roles in tumorigenesis and for testing
their potential utility as clinical targets. Most of the pre-
vious studies of PALB2 have focused on familial breast
cancer cases with normal/wild-type BRCA1 and BRCA2
(BRCAx). We hypothesize that PALB2 genetic mutations
also exist in individuals with BRCA mutations (BRCA?).
To test this hypothesis, PALB2 germline mutations were
screened in 107 exome data sets collected from familial
breast cancer families who were either BRCA1? or
BRCAx. Two novel heterozygous mutations predicted to
alter the function of PALB2 were identified (c.2014G[C,
p.E672Q and c.2993G[A, p.G998E). Notably, both of
these mutations co-existed in BRCA1? and BRCA1x
families. These studies show that mutations in PALB2 can
occur independent of the status of BRCA1 mutations, and
they highlight the importance to include BRCA1? families
in PALB2 mutation screens.
Keywords BRCA1 ! PALB2 ! Familial breast cancer !
Predisposition
Abbreviations
PALB2 The partner and localizer of BRCA2
BRCA1 Breast cancer 1, early onset
BRCA2 Breast cancer 2, early onset
MAF Minor allele frequency
LOVD Leiden open variation database
Introduction
Partner and localizer of BRCA2 (PALB2), plays important
roles in double-stranded DNA damage repair through in-
teraction with BRCA1, BRCA2, and RAD51 [1, 2]. Studies
by Xia et al. (2007) determined that homozygous mutations
in PALB2 cause Fanconi’s anemia [3]. Subsequent studies
by Chen et al. (2008) and Janatova et al. (2013) found that
women with a clear family history of breast cancer and
carried heterozygous mutations in PALB2 had an increased
risk of developing familial breast cancer [4, 5]. Further, a
large-scale study by Antoniou et al. (2014), which involved
362 members of 154 BRCAx breast cancer families with
PALB2 mutations, indicated that the risk carriers of
heterozygous PALB2 mutations have for developing breast
cancer by age 70 are as high as 35 % [6]. This risk is much
greater than previously thought and is similar to that caused
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by BRCA2 mutations, which are well known to predispose
women to breast and ovarian cancer [7]. Moreover, the
higher rate of PALB2 mutations implies the high risk of
developing breast cancer in the carriers. Thus, PALB2
mutations can potentially serve as genetic markers for the
clinical diagnosis, treatment, and prognosis of breast can-
cer. However, before this can occur, it is necessary to de-
termine the full spectrum of PALB2 mutations in familial
breast cancer. This can be accomplished by screening a
large number of families with a history of breast cancer for
PALB2 mutations [8], similar to the extensive searches for
BRCA1 and BRCA2 mutations (https://research.nhgri.nih.
gov/projects/bic/).
It remains undetermined if PALB2 mutations are
specifically present in familial breast cancer with normal/
wild-type BRCA1 and BRCA2 (BRCAx) or if PALB2 mu-
tations universally predispose individuals to familial breast
cancer regardless the mutation status of BRCA1 and
BRCA2. This knowledge is expected to help determine if
PALB2 germline mutations can be used as specific markers
to BRCAx familial breast cancer or if PALB2 germline
mutations can be used as general markers for familial
breast cancer. Most efforts made toward locating PALB2
mutations have screened cases of BRCAx familial breast
cancer [7, 8]. Our study extends to include breast cancer
family members who inherited damage mutations in
BRCA1 (BRCA1?). We analyzed PALB2 germline muta-
tions in 107 cases of both BRCA1? and BRCAx familial
breast cancer and identified two heterozygous mutations
predicted to damage the function of PALB2 (c.2014G[C,
p.E672Q and c.2993G[A, p.G998E). Most importantly,
both mutations were shared between BRCA1? and BRCAx
familial breast cancer families.
Materials and methods
Informed consent was obtained from all study participants.
Institutional Review Boards (IRBs) at both the University
of Nebraska Medical Center and Creighton University
School of Medicine approved the study.
Exome sequencing and DNA mapping processes applied
have been described in previous studies [9–11]. Briefly,
samples that were screened for PALB2 mutations included
both BRCA1? and BRCAx carriers (Table 1). Exome li-
braries were constructed using TruSeq Exome Enrichment
Kit (Illumina, Inc., San Diego, CA). A HiSeqTM 2000 se-
quencer (Illumina) was used to collect exome sequences
with paired-end reads (2 9 100). Sequences were then
mapped to the human genome reference sequence hg19
using a sequence alignment tool, Bowtie2 [12]. Next,
VarScan 2 software was used to call the variants from the
mapped sequences [13]. These variants were then
annotated using ANNOVAR [14], the PALB2 reference
sequence NM_024675 [RefSeq; National Center for
Biotechnology Information (NCBI)], Single Nucleotide
Polymorphism Database 137 (dbSNP137), the 1000 Gen-
omes Project [15], and the Exome Variant Server 6500
(http://evs.gs.washington.edu/EVS/). From the called vari-
ants, those originating in the PALB2 coding region were
selected for further analysis. Variants that caused synony-
mous changes in PALB2 were removed. From the re-
maining variants, those that caused damaging
consequences were further predicted using both sorting
intolerant from tolerant (SIFT) [16] and PolyPhen-2 [17]
programs, and then validated using Sanger sequencing.
Results
To identify the damage mutations in PALB2, exome data
were mined from 107 cases from 58 different families
with familial breast cancer (Table 1). Of these 107 cases,
56 were from 26 families with BRCA1? and 51 were
from 32 families with BRCAx; 104 cases were women,
and three cases were men; 77 cases were diagnosed with
breast cancer, and 30 cases were unaffected family
members.
Ninety variants across the entire PALB2 genomic region
were identified from the exome data. Six variants were in
coding exons, of which two were synonymous, and four
were nonsynonymous. Using Sanger sequencing, the two
nonsynonymous mutations were confirmed as c.2014G[C,
p.E672Q, and c.2993G[A, p.G998E (Table 2, Fig. 1a).
Further, both SIFT and PolyPhen-2 programs predicted
each mutation to damage the function of PALB2. Each
mutation is listed in dbSNP137 at minor allele frequency
(MAF) of 0.024 and 0.018, respectively. Notably, neither
mutation was reported in the PALB2 study by Antoniou
et al. [6], but both mutations were listed in the PALB2
LOVD database (LOVD v.2.0 Build 36). The mutation
c.2014G[C, p.E672Q, was located at the MRG15
Table 1 Exome-sequenced cases








Breast cancer – 77
No breast cancer – 30
Breast Cancer Res Treat
123
	   107 
	   	   	  
  
interaction domain, and the mutation of c.2993G[A,
p.G998E, was located at the BRCA2, RAD51, and POLH
interaction domain (Fig. 1b).
The mutation of c.2014G[C, p.E672Q, was detected in
three families with BRCA1? (families 1, 2, and 3), and the
same mutation was also detected in three families with
BRCAx (families 4, 5, 6). Similarly, the mutation
c.2993G[A, p.G998E, was detected in two families with
BRCA1? (families 2 & 3) and three families with BRCAx
(families 4, 5, 6). Interestingly, the mutation of
c.2014G[C, p.E672Q, detected in BRCA1? family 2 was
present in an unaffected family member, suggesting that
this mutation had low penetrance in this individual. The
two mutations were distributed in eight cases from three
BRCA1? families and six cases from three BRCAx
families. The data also indicate that multiple mutations in
PALB2 can exist in the same family. Figure 2 shows the
pedigree of each BRCA1? family. Each family contains
the following different mutations in BRCA1: ins6kbEx13-
ter1460 (family 1), 332-11T-Gins59-ter75 (family 2), and
300Cys-Gly (T-G) (family 3). The distribution in BRCAx
families cannot be determined because only the proband
DNA samples in each family were available for the study.
However, further studies that extend to BRCAx families are
expected to help better quantify this distribution.
Discussion
Germline mutations in PALB2 have been considered
specific to BRCAx familial breast cancer [5, 6, 18]. How-
ever, and importantly, our analysis shows that the same
germline mutations can be present in both BRCA1? and
BRCAx families. This finding suggests that PALB2 muta-
tions can occur independently of the BRCA status. Further,
it suggests that, in addition to BRCAx breast cancer
families, BRCA1? breast cancer families should be in-
cluded in PALB2 screening. Notably, each mutation iden-
tified in this study is listed in the dbSNP, which could
suggest that they are normal polymorphisms. However, the
two mutations are rare in the normal population, as judged
by their low MAF value (0.024 for c.2014G[C, p.E672Q,
and 0.018 for c.2993G[A, p.G998E). Moreover, rare
variants are known to enrich genetic predispositions for
familial diseases [19], as demonstrated by rare variants in
XRCC2, FANCC, and BLM that have been found to be
genetic predispositions for familial breast cancer [20–24].
Further, six of the 50 PALB2 damage mutations identified
in the study by Antoniou et al. (2014) were also rare
variants [6]. Our study suggests that an even greater
Table 2 Two mutations identified in PALB2




Family dbSNP138 MAF LOVD SIFT PolyPhen-2
Score Prediction Score Prediction











Fig. 1 Mutations in PALB2. a Sanger sequencing validation showing
the two mutations was heterozygous mutations in PALB2. b Location
of the two mutations of c 2014G[C p.E672Q and c.2993G[A
p.G998E in PALB2
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Fig. 2 Pedigree of the three BRCA1 ? familial breast cancer
families with the two mutations in PALB2. BRCA1 mutations in the
three families are family 1 (ins6kbEx13-ter1460), family 2 (332-11T-
Gins59-ter75), and family 3 [300Cys-Gly (T-G)]. Exome data from
eight members in family 1, two members in family 2, and two
members in family 3 were used in the study
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number of PALB2 mutations can exist in familial breast
cancer, particularly in families with BRCA1?. Additional
screens in more BRCA1? breast cancer families are needed
to confirm this observation as well as to determine if
screening for PALB2 is needed regardless the status of
BRCA1, BRCA2, and other genes that predispose indi-
viduals to breast cancer. Such a large-scale screen would
allow for the entire spectrum of PALB2 mutations to be
mapped in order to reveal their roles in familial breast
cancer.
Exome data used in this analysis were also used in our
previous studies. As such, a logical question arises; why
were these mutations in PALB2 not identified in the pre-
vious studies? Our analysis of the mapping data shows that
most of the PALB2 variants called in current study had
lower sequence coverage, which is a known phenomenon
for exome sequence data [25]. Similarly, these variants
were under the threshold for variant call conditions used in
our previous studies. Thus, focusing on PALB2-mapped
sequences, lowering the cut-off values for variant calls, and
using Sanger sequencing for validation allowed us to
identify missed variants. Notably, an extensive amount of
exome data has been generated from breast cancer genomic
studies [26, 27]. Our study shows that targeted mining of
existing exome data plus Sanger validation is a powerful
approach to identify the mutations in specific genes. In
summary, our study shows that mutations in PALB2 can
occur independent of the status of BRCA1 mutations.
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